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 The objective of present study is to develop bilayer abuse-deterrent extended-
release tablets (ADERTs) using various model drugs for opioids overdose crisis. Bilayer 
ADERTs using various model drugs were fabricated by direct compression; consists of 
extended-release drug layer and pH modifying layer. To develop extended-release layer, 
various hydrophilic polymers evaluated for their abuse deterrent potential. Based on 
significantly higher viscosity at 100RPM and lower syringe-ability data, it was found that 
HPMC K100M could be used as abuse deterrent polymer. Along HPMC K100M, various 
diluents were evaluated for their abuse deterrent potential. Tablet formulations prepared 
with various type of diluents using metformin HCl as model drug. Based on outcomes, 
MCC KG-1000 was selected as diluent to provide tablets with physical and/or chemical 
barrier. Bilayer ADERTs were developed to minimize multiple-unit oral abuse using three 
model drugs based on similar pKa values to that of opioids, i.e., propranolol HCl (pKa 
9.45), quinidine sulfate (pKa 8.5), dipyridamole (pKa 6.59). Various alkalizing agents 
evaluated for their abuse deterrent potential. Bilayer ADERTs using propranolol HCl as 
model drug were fabricated. Based on outcomes, magnesium hydroxide was selected as 
alkalizing agent, since it raised pH of dissolving media near to pKa of all model drugs. 
Additional amount of magnesium hydroxide was incorporated in extended-release layer to 
 
minimize drug release in both FaSSGF and FaSSIF upon multiple-unit ingestion evaluated 
by in-vitro drug release study. Formulated bilayer ADERTs provided similar drug release 
profiles as compared to conventional extended-release tablets for single-unit ingestion. 
However, upon ingestion of multiple-unit bilayer ADERTs, fast-dissolving pH modifying 
layer increases pH in dissolving media, while extended-release layer increases micro-
environmental pH within tablets for all model drugs tested. Retarding drug release owing 
to low solubility of basic drug at higher pH was observed. To minimize intravenous abuse, 
drug extraction study in various solvents were evaluated. Drug extraction was found to less 
than 2% for all the model drugs tested due to effect of alkalizing agent. Therefore, 
application of alkalizing agent has impact on pH-dependent solubility of drug like opioids 
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 1 
1. INTRODUCTION 
There are approximately 100 million Americans suffering from chronic pain that 
costs up to $635 billion in medical costs (1). Opioid therapy is a necessary component of 
chronic pain management for many patients (2). Opioids are widely prescribed to treat 
most severe cases and over the past two decades, the number of prescriptions have also 
increased considerably (3). Consequently, while remaining as the major therapeutic 
option for the treatment of chronic pain, prescription opioids are the drugs of choice for 
abuse to increase the euphoric effect (e.g. feeling intense excitement and happiness). An 
estimated 25.4 million people have reported non-medical use of opioids in the last two 
decades and 18,893 drug overdose deaths involving prescription opioid in 2014 (4). 
Moreover, according to one of the national surveys, it has been reported that teenager 
group is the major constituent of non-medical use of opioids (5,6). 
 
Opioids are available in various dosage forms including oral solutions, tablets, 
and capsules as well as parenteral solutions and can be abused via different methods to 
increase euphoric effect. For instance, oral solutions can be abused by ingesting high 
dose or by injecting the solution via parenteral route to achieve euphoria. Similarly, 
parenteral solutions can be injected in higher dose to get euphoric effect. Tablets are 
abused by different methods such as by crushing tablets to get smaller particles, which 
can be abused by nasal insufflation. Also, the intact tablets or manipulated tablets (being 
crushed into smaller particles) can be dissolved in commonly available solvents (e.g., 
water, vinegar, alcohol, and 70% isopropanol) making it suitable for parenteral 
administration. Among the different available dosage forms of opioids, oral tablets are 
 2 
most commonly abused (7). Hence, there is critical need for the development of a suitable 
dosage form to help minimize abuse via parenteral, nasal and oral routes.  
 
Recently, several dosage forms are being developed to decrease the abuse 
potential of opioid medications. Dosage forms equipped with these abuse deterrent 
features are commonly called abuse deterrent formulations. It is believed that these 
formulations have the potential to decrease abuse without limiting access of opioids to 
legitimate patients (8). In general, abuse deterrent formulations lower the abuse 
desirability of a medication by preventing physical (e.g., crushing, chewing of tablets) 
and chemical (e.g., drug extraction from tablets) tampering, prohibiting drug metabolism 
or binding, and/or incorporating aversive materials (e.g., bittering agents and mucous 
membrane irritants) into the product (9). Due to presence of higher dose in extended 
release formulations as compared to immediate release formulations, extended release 
formulations are at higher risk of abuse. As a result, it is recommended by the FDA to 
develop abuse deterrent properties for extended release formulations. The present 
investigation focuses on developing abuse deterrent extended release opioid tablets using 
excipients as physical and/or chemical barrier to minimize the potential problem of 
opioid abuse.
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2. LITERATURE REVIEW 
2.1. Abuse of opioids  
Opioids act on the  receptor in the spinal cord and brain to reduce pain (10). 
Activation of the  receptor releases substance P in the spinal cord, this is the central 
neurotransmitter for pain which mediates analgesic effects (10–12). In addition, the  
receptor in the brain is dominant to euphoria (a feeling or state of intense excitement and 
happiness) that leads to abuse of opioids (12). Euphoria involves the dopaminergic 
system which is implicated in all addictive behavior, including that of alcohol and 
nicotine (13). 
 
Majority of the currently available opioid dosage forms (e.g., tablets, capsules 
etc.) are designed for oral administration making tablets and capsules easy targets of 
abuse. Indeed, several recent drug preference studies have shown oral tablets to be the 
major source of abuse/misuse of prescription opioids. The opioids with most drug 
product approvals in the U.S. are oxycodone, hydrocodone, codeine and morphine. In 
addition, due to presence of higher dose in extended release opioid formulations, they are 
at higher risk for abuse over immediate release formulations. Drug abusers opt for 
various forms of abuse and product tampering. They may choose to ingest multiple doses 
of a drug product or may manipulate (e.g., crush, cut, chew, grind, heat, and/ or dissolve) 
the drug product to yield a high amount of opioid that could be easily abused via 
ingestion, nasal insufflation, injection, or smoking. The preferred route of abuse is 
governed by multiple factors such as the type of abusers and their tolerance level. For 
example, as a beginner, abuser starts with ingesting multiple oral tablets to get euphoric 
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effect. Over time, they might develop tolerance or look for quick euphoric effect 
developing preference for intravenous injection or nasal insufflation. For intravenous 
injection, abusers crush the tablets and dissolve it in various solvents (e.g., water, ethanol, 
and 70% isopropanol) making it suitable for injection. Also, they crush tablets to get 
smaller particles that are suitable for nasal insufflation and smoking (14,15).  
 
To reduce opioid abuse, pharmaceutical manufacturers have responded to this 
public health concern by developing dosage forms resilient to various forms of 
tampering, best known as abuse deterrent formulations (ADFs). Although any type of 
dosage form can be formulated to deter abuse, oral dosage forms particularly oral solids, 
have seen the most use of novel technologies by applying various manufacturing methods 
and formulation designs. The ultimate goal of an ADF is to produce a product less 
favorable to abuse and misuse. This can be extended to include products with the ability 
to prevent, discourage or decrease the feeling of euphoria, high or rush sought after by 
abusers. A further challenge lies in making the product safe and effective when taken as 
directed. Hence, the purpose of this research is to develop a dosage form that would be 
resistant to all well-known methods of abuse and tampering. 
 
 2.2. Opioid products currently developed to have abuse deterrent properties 
Opioid products, especially available in extended release dosage forms, are 
currently being developed to have abuse deterrent properties are described in Table 1. 
Based on Table 1, physical barrier using various polymers/excipients, such as 
polyethylene oxide (PEO), xanthan gum, hydroxypropyl methyl cellulose (HPMC), 
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lipids, fatty acids and wax, is the most commonly used approach to minimize drug abuse. 
These polymers/excipients have the ability to provide both physical barrier as well as 
extended drug release characteristics. Among these polymers/excipients, PEO is the most 
widely used one (i.e., eight out of twelve products listed in Table 1).  
 
Another popular approach for abuse deterrence includes use of aversive agents 
used in seven out of twelve products listed in Table 1. The inclusion of aversive agents 
produces undesired effects when the product is abused. For example, sodium lauryl 
sulfate, a commonly used surfactant, irritates mucous membranes when tablet is crushed 
and abused via nasal insufflation. Also, the use of staining agents, which may stain the 
nasal and oral cavities when abusers snort or inhale the altered drug, causing 
embarrassment. 
 
Although two extended release capsules and one immediate release tablet dosage 
forms are listed in Table 1, majority of the products being developed are extended release 
tablet dosage forms, as these are at higher risk of abuse due to higher drug content. 
Hence, the present investigation focuses in the development of abuse deterrent extended 
release tablet dosage forms using excipients to have physical and/or chemical barrier.  
 
2.3. Formulation approaches of abuse deterrent extended release tablets (ADERT) 
Various abuse-deterrent formulation approaches have been developed to minimize 
manipulation of the dosage forms. These approaches include 1) inclusion of physical 
barriers to prevent crushing and extraction, 2) chemical modifications to hinder excessive 
 6 
drug release when manipulated, 3) inclusion of aversive agents to induce an unpleasant 
experience, and 4) use of antagonists to block the opioid effect when abused (16–19). 
However, in order to retain the extended release characteristics of abuse deterrent tablet 
formulation, polymers/excipients should be selected based on both abilities to provide 
physical barrier and extended drug release characteristics. 
 
2.3.1. Selection of polymers 
There are various classes of polymers, such as hydrophilic polymers, lipids, 
hydrophobic polymers and biodegradable polymers, utilized in preparation of extended 
release tablets. These polymers are described in Table 2. Hydrophilic polymers are the 
most widely used polymers to prepare extended release tablets. They are further 
classified into various categories such as natural gums, cellulose derivatives, non 
cellulose natural, non cellulose semi-synthetic polymers and polymers of acrylic acid. 
PEO is a hydrophilic polymer, which has been used to prepare extended release abuse 
deterrent tablets. Moreover, there are many hydrophilic polymers as described in Table 2, 
may have potential to provide not only the extended release characteristics but also abuse 
deterrent properties by acting as a physical and/or chemical barrier. 
 
2.3.2. Effect of excipients as physical barrier on ADERT 
Excipients as a physical barrier are classified into various categories based on 
their material characteristics which are poly(ethylene oxide), sucrose acetate isobutyrate, 
hyper-absorbent materials, lipids, foaming agents, and ceramic nanoparticles. In addition, 
novel microcrystalline cellulose grades have good compression characteristics that 
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increase hardness of tablets. The higher hardness of tablet may be beneficial to prepare 
abuse deterrent tablets making it difficult to crush into smaller particles.  
 
2.3.2.1. Poly(ethylene oxide) 
Poly(ethylene oxide) (PEO) is a high molecular weight polymer that undergoes 
ductile deformation rather than brittle fracture under mechanical stress, thereby 
preventing pulverization upon crushing and act as a physical barrier. PEO is also miscible 
and when it comes into contact with water, PEO hydrates rapidly and eventually turns 
into a viscous solution or gel which will make it difficult to extract the drug (20). PEO is 
available in a wide range of grades of differing viscosity with average molecular weights 
ranging from 100,000 to 7,000,000 manufactured by the Dow Chemical Company. 
Degree of swelling characteristics of PEO increases with increasing molecular weight 
(21,22). 
 
2.3.2.2. Sucrose acetate iso-butyrate 
Sucrose acetate isobutyrate (SAIB) is a hydrophobic, water-insoluble, thermally-
stable, liquid and a biodegradable excipient (23). It is used in an extended-release 
formulation of a hard-shell gelatin capsule filled with an SAIB-based viscoelastic matrix. 
SAIB remains highly viscous over a wide range of temperature from 80C to 100C. The 
Remoxy matrix is reported to have a viscosity of greater than 60,000 mPas, which is 
approximately 34 times more viscous than honey. This high viscosity prevents the 
Remoxy formulation from being drawn or pushed through a syringe and prevent 
physical manipulation. Therefore, the formulation cannot be abused via intravenous 
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injection. Since it remains a viscous liquid when frozen, the Remoxy formulation is 
also resistant to freezing and crushing (24). 
 
2.3.2.3. Superabsorbent materials 
Super-absorbents are cross-linked acrylic polymers such as polycarbophils or 
carbomers which can absorb a large quantity of water. Polycarbophils are cross-linked 
with divinyl glycol, while carbomers are cross-linked with either allyl sucrose or allyl 
pentaerythrol. Both polycarbophils or carbomers can absorb greater than 62 gm water/gm 
material per USP specifications, and both materials can swell to approximately 1000 
times their original volume when exposed to a pH environment above 4–6. Hence, it will 
solidify upon contact with aqueous solvent and prevent syringe-ability and extraction. 
Xanthan gum and hypromellose are present as the superabsorbent material in the 
MORPHABOND extended-release morphine sulfate tablet. This tablet was developed 
by Inspiron Delivery Technologies, LLC, and approved in 2015 that consists of an 
expansion layer, a barrier layer, a drug-containing diffusion layer, an extended-release 
coating, and a color coating (24). 
 
2.3.2.4. Lipids  
Lipid-based formulations can be useful in abuse-deterrent formulations, because 
of their lipophilicity and low solubility in ethanol. Hence, prevents extraction of drug 
upon dissolving in aqueous and hydroalcoholic solvents. In some cases, they have also 
demonstrated increased mechanical strength of the dosage forms (25–28). Examples of 
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waxes include carnauba wax and beeswax. Waxes are hydrophobic and have a melting 
point similar to that of fatty acids. 
 
2.3.2.5. Ethyl cellulose 
Cima Labs Inc. has developed OraGuard process of including wax in coating 
layer of granules that gives crush resistant properties. In this technology, the core 
granules consist of opioid and cellulosic polymers such as hypromellose or ethyl 
cellulose, whereas the coating is composed of ethyl-cellulose and 10–30% glyceryl 
behenate. Coated granules can eventually be formulated in a matrix tablet with 
hypromellose and lactose. The inclusion of glyceryl behenate instead of magnesium 
stearate in the coating layer enabled an increased crush resistance. Crushed granules with 
lipids released less than 21% of the opioid in 30 minutes, which is less than crushed 
granules without lipids. Additionally, glycerides and waxes prevent dose dumping in 
ethanol, owing to their low solubility in ethanol (24). 
 
2.3.2.6. Foam-forming agents 
A foam-forming delivery system has been developed by Acura Pharmaceuticals to 
deter drug abuse (24). The foam-forming agents are composed of effervescent mixtures 
that contain an organic acid and base (e.g., citric acid and sodium bicarbonate), a 
surfactant (e.g., sodium lauryl sulfate), and high- and low-viscosity polymers formulated 
in a tablet. Polymers are added as a foam stabilizer. Low-viscosity polymers exhibit rapid 
hydration and gelation upon contact with a suitable media and can therefore entrap gas 
(e.g., CO2) emitted by the effervescent agents into the foam. Due to its ability to stabilize 
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the foam more effectively, a high-viscosity polymer is preferred over a low-viscosity 
polymer. High viscous polymer prevents syringe-ability and extraction of drug and 
minimize abuse via parenteral route.  
 
2.3.2.7. Titanium dioxide 
Altair Nanotechnologies has developed proprietary technologies to manufacture 
nanoparticles of titanium dioxide and other related ceramic compounds. These ceramic 
structures are spherical and have a hollow core that allows for a high-loading drug 
coating. The hydrophilicity or hydrophobicity of the nanostructures can be adjusted to 
influence the nanoparticles’ capacity to uptake the drug into the hollow core via chemical 
modification. These nanoparticles can be loaded with opioids using solvent evaporation 
or a melt-coating process. Extreme mechanical strength is associated with ceramic 
nanoparticles loaded with opioids and present a controlled-release delivery system. They 
are resistant to diversion attempts such as grinding and prevent abuse via nasal and 
parenteral route (24). 
 
2.3.2.8. Microcrystalline cellulose 
The novel microcrystalline cellulose (MCC) grades, such as MCC KG-802, KG-
1000, UF-711 and UF-702, have good flow properties as well as good compatibility 
owing to their various particle shape characteristics. These novel polymers can give high 
hardness characteristics upon compression to get physical barrier. The most widely used 
MCC grades for oral solid dosage forms are PH grades. MCC PH-101 is the standard 
grade and most widely used for wet granulation tableting. PH-102 has larger particle size 
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with improved flow while maintaining compatibility and disintegration properties similar 
to PH-101 and used mostly for direct compression tableting. 
 
The MCC UF grades contain porous structures and more spherical morphology of 
CEOLUS UF grades contribute to their effective plastic deformation and better flow. 
They are highly compactible and flowable. They are useful for direct compression. On 
the other hand, for MCC KG grade, the key to the compactibility of the CEOLUS KG 
grades lies in their needle-like particle shape. Needle-like particles, once compressed, 
have less elastic recovery and more particle-to-particle entanglements to provide greater 
tablet hardness. In particular, KG-1000, offers practically required tablet hardness and 
friability at concentrations of 10% or less. 
 
 2.3.3. Effect of excipients as chemical barrier on ADERT 
The use of chemical barrier approach hinders excessive drug release when the 
dosage form is manipulated. There are many approaches available which includes salt 
formation between opioids free base and fatty acids that makes drug more lipophilic, 
complexation with ion exchange resin which will release drug by exchange of ions in 
gastrointestinal track. In addition, the use of alkalizing agent may serve as a chemical 
barrier that will reduce or hold drug release when multiple tablet is ingested. 
 
2.3.3.1. Salt formation between opioids free bases and fatty acids  
DETERx was developed by Collegium Pharmaceutical Inc. in 2016 which is an 
abuse-deterrent drug delivery system is a capsule that contains microparticles consisting 
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of fatty acid salts of opioid free bases along with excess fatty acids and waxes. This 
technology minimizes drug extraction by altering solubility of drug. Fatty acids cause 
opioids to become much more lipophilic as compared to counter ions such as 
hydrochloride, sulfate, and bitartrate. With different carbon chain lengths of fatty acids, 
lipophilicity of the fatty acid salts can be adjusted. Fatty acid salt formation is 
accomplished by a melt process. During manufacturing, opioid free base is dissolved in 
molten fatty acid (e.g., stearic acid and myristic acid), which is in molar excess relative to 
the drug in order to achieve a homogeneous single phase (2–15 times). Waxes (e.g., 
beeswax and carnauba wax) can eventually be added to the molten solution, which is then 
converted into spherical particulates using a spray congealing process. The spherical 
particulates are then filled into hard gelatin capsule shells. The microparticles do not 
dissolve in water or organic solvents. Solubilization of opioids in the matrix enhances the 
abuse-deterrent properties of microparticles, as it is difficult to extract the drug from an 
intimately mixed composition. Since most of the drug remains associated with or 
entrapped within the fatty acid, the release of the drug is slow even if these microparticles 
are chopped or crushed (24).  
 
2.3.3.2. Complexation with ion exchange resins  
Drug delivery based on ion exchange resins (IERs) are used for taste masking and 
extended release (29–31). Ion exchange process is defined as the reversible interchange 
of ions between a liquid and a solid phase (32). IER-based formulations possess better 
dose dumping prevention properties than conventional polymeric formulations, since 
drug release from resinate is regulated by both ionic (chemical) and polymeric (physical) 
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mechanisms. Release of the active ingredient is triggered by ion exchange reaction with 
counter ions present in gastrointestinal tract. Acidic resins are used for delivery of 
opioids. Resins differ in their exchange capacity, permeability (related to their degree of 
cross-linking), swelling potential, and particle size. Strong acidic resins behave similarly 
to strong acids, and they are highly ionizable, producing many ions for the exchange 
process. On the contrary, weak acidic resins are weakly dissociated and have fewer ions 
available for exchange (33).  
 
2.3.3.3. Alkalizing agent  
Use of alkalizing agent in formulation, under normal dosing conditions, may 
allow complete and/or bioequivalent oral delivery of the desired drug dose from the 
formulation. However, when excess doses are ingested, either intentionally or 
unintentionally, the formulations may work to either slow or block release and 
subsequent absorption of the excessive doses. As opioid drugs are weakly basic in nature 
and have good dissolution in acidic environment (stomach), the dissolution of these drugs 
can be reduced by incorporating alkalizing agent in the tablet in sufficient amount that 
will release the drug under normal dosing condition. However, when the tablets taken in 
multiple dose, it will change the pH of stomach to hinder the release and absorption of 
the drug. The alkalizing agents will raise the pH of stomach and the drug will remain as 
insoluble particles. These alkalizing agents include sodium bicarbonate, magnesium 
hydroxide, calcium carbonate, magnesium carbonate, aluminum hydroxide (34). Also use 
of alkalizing agent in the tablet formulation leads to change in microenvironmental pH 
and which leads to reduction in drug release upon ingestion of multiple units.
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2.3.4. Effect of antagonists on ADERT 
The use of antagonist along with agonist (opioids) into the formulation has been 
proven to be a successful strategy to deter the abuse of opioid drugs. The euphoric effects 
of opioids can be blocked when these products are subject to tampering due to high 
concentration of antagonist in plasma. Antagonists can be categorized as available 
antagonist and sequestered antagonist. The term available antagonist refers to the 
antagonist being absorbed when opioid drugs are taken properly by patients. Otherwise, 
the term sequestered antagonist is used. Table 3 represents a list of products that contain 
antagonists. As shown in Table 3, naltrexone hydrochloride (five out of seven products as 
listed in Table 3) and naloxone hydrochloride (two out of seven products as listed in 
Table 3) are two commonly used antagonists. Because of its high bioavailability and high 
activity (2–9 times that of naloxone), naltrexone hydrochloride becomes very harmful to 
patients if absorbed along with opioids. Therefore, naltrexone hydrochloride is always 
sequestered.  
 
2.3.5. Effect of aversion agents on ADERT 
The inclusion of aversive agents is a formulation technique which is older than 
use of antagonists to produce undesired pharmacological effects when the product is 
abused. The immediate release LOMOTIL tablet, approved in 1960 to treat diarrhea, 
contains 2.5 mg diphenoxylate hydrochloride as the therapeutic agent and 0.025 mg 
atropine sulfate as the aversive agent. Atropine sulfate, an anticholinergic agent, causes 
tachycardia (i.e., rapid pulse rate, shortness of breath, and dizziness) when an excessive 
number of tablets are ingested. Table 4 represents a list of commonly used aversion 
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agents. There are various categories of aversive agents such as bittering agent, emetic 
agent, gelling agent, irritant agent, laxative agent, staining agent and vasodilator. These 
aversive agent cause discomfort such as vomiting, induce pain/irritation, itching to 
abusers when they try to manipulate and abuse the dosage form. Hence, the use of 
aversive agent is another approach along with the use of physical and chemical barrier to 
prepare abuse deterrent extended release tablet to minimize abuse of opioids. 
 
2.4. Selection of model drug as alterative of opioids 
To avoid dealing with the complexity of controlled substance licensing and its 
management, various model drugs with similar physicochemical properties have been 
selected. Metformin HCl was selected as a model drug based on its aqueous solubility 
which is similar to a widely abused opioid drug oxycodone hydrochloride (35).  
 
Also, various model drugs with similar dissociation constant (pKa) values to that 
of opioids have been selected. Opioids are weak bases with pKa values in the range of 
6.5-9.5 (Table 6). In dissolution media, these drugs have different dissolution profiles 
depending on the pH of the media and their pKa value. For example, weakly basic drugs 
have a higher solubility in acidic media, and that leads to an increase in drug release from 
the tablet. On the other hand, there is a decrease in the solubility of opioids with an 
increase in the pH of the media, which leads to a decrease in drug release (36). For this 
reason, three model drugs were selected based on a similar pKa value that covers higher 
(9.5), median (8.6), and lower (6.5) pKa ranges compared to opioids. Propranolol HCl 
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(pKa=9.5), quinidine sulfate (pKa=8.5), and dipyridamole (pKa=6.4) were selected as 
model drugs.
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3. RESEARCH OBJECTIVES AND SPECIFIC AIMS 
The primary objective of this research is to develop abuse deterrent extended 
release metformin tablets using excipients as physical and/or chemical barrier to 
minimize the potential problem of opioid abuse. 
Specific aims include 
• To select suitable polymer and determine its effect as a physical and/or 
chemical barrier. 
• To determine effect of diluents as a physical barrier. 
• To study the effect alkalizing agent as a chemical barrier. 
• To formulate tablet dosage form using selected extended release polymer, 
diluent using various model drugs. 
• To study the effect of alkalizing agent as a chemical barrier on ADERT using 
various model drugs. 
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4. MATERIALS AND METHODS 
4.1. Materials 
Metformin HCl ( 99%), propranolol HCl ( 99%), quinidine sulfate dihydrate ( 
98%), and dipyridamole were purchased from TCI America (Cambridge, MA). Xanthan 
gum, corn starch, gelrite gum, chitosan, locust bean gum, sodium carboxymethyl 
cellulose (Na CMC), hydroxypropyl cellulose (HPC) were purchased from Sigma 
Chemicals (St. Louis, MO). Carbopol 940 was purchased from Acros Organics (New 
Jersey, USA). Polyethylene oxide (PEO) and Hydroxypropyl methyl cellulose (HPMC)  
of various grades were kindly provided by DOW Chemicals (Midland, MI) and Ashland 
Pharmaceuticals (Wilmington, DE), respectively. Microcrystalline cellulose (MCC) PH 
grades were purchased from Sigma Chemicals (St. Louis, MO). MCC UF and KG grades 
were kindly provided as a gift sample by Asahi kasei corporation (Japan, Tokyo). 
Magnesium hydroxide, calcium carbonate, aluminum hydroxide, and calcium hydroxide 
were purchased from VWR International (Radnor, PA). All solvents utilized in the study 
were of analytical grade and were obtained from Thermo Fisher Scientific (Fair Lawn, 
NJ). 
 
4.2. Analytical method for various model drugs  
4.2.1. Metformin HCl 
Analysis of metformin HCl was carried out by a UV spectrophotometer. The 
accurately weighed drug was dissolved in distilled water to prepare a stock solution of 1 
mg/mL. The solution was further diluted to prepare solutions of 2-10 μg/mL. The diluted 
solutions were analyzed at an absorbance wavelength of 232 nm (35).The calibration 
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curve was generated using the concentration vs absorbance curve and represented in 
Figure 1. 
 
4.2.2. Propranolol HCl 
Propranolol HCl was analyzed using an HPLC system (Agilent Technologies Inc., 
Santa Clara, CA) equipped with HP1100 quaternary pump and autosampler. The system 
had a UV detector, which was set at 290 nm. Samples were analyzed for propranolol HCl 
concentrations using a C18, 4 µm 150×4.6 mm column (Phenomenex, CA). Isocratic 
conditions with a flow rate of 0.8 ml/min were used. The mobile phase was prepared by 
dissolving 0.5 g of sodium dodecyl sulfate (SDS) in 18 mL of 0.15 M phosphoric acid 
and adding 90 mL of acetonitrile and 90 mL of methanol to this mixture, this solution 
was then diluted with Nanopure® water to 250 mL, mixed, filtered, and degassed. The 
injection volume was 10 µL. Data acquisition and processing were performed using 
Chemstation® software (Agilent Technologies Inc., Santa Clara, CA) (37). Area under 
the peak was used to calculate the concentration of propranolol HCl and linearity over 
concentrations ranging between 25-1000 μg/ml, which was established as shown in 
Figure 2. 
 
4.2.3. Quinidine sulfate 
Quinidine sulfate was analyzed using an HPLC system with a 4 mm × 100 mm C-
18 column with a particle size of 5 μm (ChromTech, MN). The mobile phase was 
composed of mixture of Nanopure® water, acetonitrile, methanesulfonic acid solution 
(35.0 mL of methanesulfonic acid added to 20.0 mL of glacial acetic acid, diluted with 
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water to 500 mL), and diethylamine solution (10.0 mL of diethylamine added in water to 
obtain 100 mL of solution) at ratio of 860:100:20:20. The pH of the mobile phase was 
adjusted to 3.2 with diethylamine. A flow rate of 1.2 ml/min was adjusted, and the 
quinidine sulfate content was detected at a wavelength of 331 nm (38). Area under the 
peak was used to calculate the concentrations of quinidine sulfate, and linearity over the 




Dipyridamole was analyzed using an HPLC system with a 3 mm × 150 mm C-18 
column with a particle size of 4 μm (phenomenex, CA). The mobile phase consisted of 
68% v/v methanol and 32% v/v of 0.5% v/v acetic acid aqueous solution. A flow rate of 
0.8 ml/min was set, and dipyridamole content was detected at a wavelength of 284 nm 
(39). Area under the peak was used to calculate the concentrations of dipyridamole, and 
linearity over the concentrations ranging between 25-1000 μg/ml, was established as 
shown in Figure 4.  
 
4.3. Effect of excipients as physical and/or chemical barrier on ADERT 
Abuse deterrent potential of various polymers were evaluated by determining 
their effect as a physical barrier as described in following studies.
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4.3.1. Effect of polymers as physical barrier to screen of type of polymer  
Various hydrophilic polymers were selected by evaluation of their effect as a 
physical barrier by determining swelling, viscosity, and syringe-ability studies of 
polymeric solutions.  
 
4.3.1.1. Dissolution/swelling behaviors of polymers 
The effect of hydrophilic polymer swelling in commonly used solvents [0.1 N 
hydrochloric acid (HCl), water, 70% isopropanol (IPA), 10% ethanol, and 40% ethanol 
(EtOH)] was determined by dissolution/swelling behavior study for drug extraction. 
Hydrophilic polymers dissolve and swell in aqueous medium, and form gel which retards 
diffusion of drug from the hydrophilic matrix, and thereby tablets prepared with these 
polymers reduce drug extraction in various solvents. Solvent selection was based on the 
availability of solvents and has been used by abusers. 
 
Polymeric solutions (2% w/v) were prepared by adding 2 gm of polymer in 100 
mL of various solvents separately and kept on overnight stirring on magnetic stirrer at 
room temperature to achieve complete hydration of polymers. The 2% w/v polymeric 
solution represents a similar concentration of 1 crushed tablet dissolved in 5-10 mL of an 
aqueous solution. The dissolution/swelling behavior was determined by visual 
observation to screen the type of polymer. The polymers that dissolve and swell in all the 
given solvents, were selected to determine their viscosity study as a physical barrier. 
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4.3.1.2. Viscosity study 
One common method of abusing tablet dosage form is extraction of the opioid 
from the tablets using a variety of commonly available solvents. Such extraction leads to 
a concentrated drug solution which can be used for parenteral abuse to achieve euphoria. 
The amount of solvent used by abusers is about 5-10 mL. The abusers also heat the 
solvents to get higher concentration solution. Hence, a polymer as a physical barrier 
should be selected based on their higher viscosity in various solvents in order to reduce 
the syringe-ability and reduce potential for intravenous injection.  
Based on these considerations, the viscosity of 2% w/v polymeric solutions 
(represents one crushed tablet in 10 mL of aqueous solvent) were determined. Viscosity 
of 2% w/v screened polymeric solutions were determined in various solvents [0.1 N 
hydrochloric acid (HCl), water, 70% isopropanol (IPA), 10% ethanol, and 40% ethanol 
(EtOH)]. Viscosity of these polymeric solutions were evaluated using Brookfield 
Viscometer (AMETEK Brookfield, MA) with spindle number S-03 at room temperature 
(25C) at spindle speed of 1-100 rpm (rotation per minute). The polymers were screened 
based on higher viscosity at 100 rpm compared to other polymers in all solvents, 
respectively. The screened polymers were evaluated for their heat-induced viscosity 
study and syringe-ability study.  
 
4.3.1.3. Heat induced viscosity study  
Viscosity of a liquid decreases with increase in temperature and the fluidity of a 
liquid (the reciprocal of viscosity) increases with temperature. The dependence of the 
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viscosity of a liquid on temperature is expressed approximately for many substances by 
an equation analogous to the Arrhenius equation of chemical kinetics (40). 





   Equation. 1 
where, 𝜂 is viscosity, A is a constant, R is a gas constant, and T is the absolute 
temperature 
 
The effect of temperature on viscosity of selected polymeric solutions were 
evaluated by heat-induced viscosity study based on the Arrhenius equation (Equation 1) 
of chemical kinetics. Heat-induced viscosity of screened 2% (w/v) polymeric solutions 
were determined in distilled water using Brookfield Viscometer with spindle number S-
03 at spindle speed range of 1-100 rpm at 25, 37, 60, and 80C to determine “activation 
energy (Ea)”. Ea is the energy required to initiate flow between polymer molecules and 
can be obtained from the slope by plotting the natural logarithm of viscosity against 
reciprocal of temperature. The higher value of Ea leads to a reduction in the flow of 
polymeric solution and that might lead to a reduction in syringe-ability upon heating.  
 
4.3.1.4. Syringe-ability study  
Polymeric solutions (2% w/v) in commonly injectable solvents (water, 10% 
ethanol, and 40% ethanol) were used to determine syringe-ability. 15 mL of polymeric 
solution was transferred to a 20 mL scintillation vial and syringe-ability was performed 
by TA.XTPlus Texture Analyzer (Texture Technologies Corp., Hamilton, MA) equipped 
with a syringe assembly set. A 5 ml syringe fitted with a 21-gauge needle was used for 
each test. Tension mode was set for 1 mm/s test speed and 0.05 N trigger force. The 
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syringe plunger was set to move a distance of 40 mm in each direction with 30 seconds 
hold time in-between pulling and pushing. The target mode was set to record force that 
the sample plunger experience while pulling the solutions. Also, the volume withdrawn in 
the syringe was recorded by visual observation as one of syringe-ability parameters.  
 
4.3.2. Preparation of metformin HCl-loaded ADERT 
The screened polymers were selected to prepare tablets with various grades of 
microcrystalline cellulose as diluent. The composition of tablets was drug, polymer, 
MCC, and magnesium stearate at ratio of 8:30:61.5:0.5 (Table 9). Drug, polymer, diluent 
and lubricant were blended together by dry mixing using mortar and pestle and made into 
tablets by direct compression at a fixed compression force using Carver laboratory press 
tablet machine (Carver Inc, IN) equipped with 12 mm round, flat, and plain punches with 
compression pressure of 2500 lbs. 
 
4.3.2.1. Abuse deterrent potential of metformin HCl-loaded ADERT 
Abuse deterrent potential of prepared ADERT was characterized in terms of 
physical and chemical barrier studies. 
 
4.3.2.1.1. Physical barrier: Screening of type of diluent  
To formulate abuse deterrent dosage form, higher hardness of tablets is required 
to minimize drug abuse by snorting, as abuser crushes tablets into smaller particles to 
snort and achieve high blood concentration of opioids and subsequent euphoric effects. 
To achieve this, various microcrystalline cellulose (MCC) grades such as MCC PH-101, 
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PH-102, UF-702, UF-711, KG-802 and KG-1000 were screened for their better hardness 
characteristics as an excipient in tablet formulations.  
 
4.3.2.1.1.1. Hardness testing  
Tablet hardness or breaking force test is used to assess mechanical strength of 
ADERT and was determined using tablet hardness tester (Pharma Alliance group Inc, 
CA). The hardness is measured in terms of kg/cm2. Three ADERTs were chosen 
randomly and tested for hardness from each formulation. The average hardness of 
triplicate determinations was recorded. The diluent that contributed to higher tablet 
hardness characteristic was selected for further studies.  
 
4.3.2.1.1.2. Syringe-ability study  
Powder sample (of prepared ADERT) of 500 mg (i.e., one tablet) from each 
formulation was weighed accurately and transferred into separate 20 ml scintillation 
vials, each containing 10 ml of commonly injectable solvents that are distilled water, 
10%, and 40% ethanol, respectively, at room temperature. The scintillation vials were 
vortexed for 30 seconds and left for hydration for 30 min before the tests. Syringe-ability 
study of ADERT powder blend was performed using similar procedure as given in 
section 4.3.1.4. 
 
4.3.2.1.2. Chemical barrier: Drug extraction study 
Drug extraction study was performed to evaluate the chemical barrier of ADERT. 
Extraction studies were performed on intact formulations to evaluate drug extraction in 
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water, 10% and 40% ethanol. Briefly, an intact tablet was added to vial containing 10 mL 
of solvent (water or ethanol). The vial was vortexed for 3 minutes before withdrawing 
samples at 5 and 30 minutes and analyzed for drug content using method described in 
section 4.2.1. The study was performed in triplicate at room temperature. 
 
4.3.3. Preparation of propranolol HCl-loaded ADERT  
The propranolol HCl-loaded ADERT was prepared using similar procedure as 
given in section 4.3.2. with use of a similar amount (40 mg) of propranolol HCl as a 
model drug. 4.3.3.1. Abuse deterrent potential of propranolol HCl ADERT 
 
Abuse deterrent potential of propranolol HCl-loaded ADERT was characterized 
in terms of physical and chemical barrier studies. The physical barrier was evaluated 
using hardness testing, evaluated by using a similar procedure as given in section 
4.3.2.1.1.1. Whereas the chemical barrier was performed by drug extraction study on the 
intact tablet to evaluate drug extraction in water, 10%, and 40% ethanol, respectively. It 
was evaluated using similar procedure as given in section 4.3.2.1.2.  
 
4.3.4. Preparation of quinidine sulfate-loaded ADERT  
The quinidine sulfate-loaded ADERT was prepared using similar procedure as 
given in section 4.3.2. with use of similar amount (40 mg) of quinidine sulfate as a model 
drug.
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4.3.4.1. Abuse deterrent potential of quinidine sulfate-loaded ADERT 
Abuse deterrent potential of quinidine sulfate-loaded ADERT was characterized 
in terms of using physical and chemical barrier studies. The physical barrier was 
evaluated using hardness testing, performed using similar procedure as given in section 
4.3.2.1.1.1. and chemical barrier was evaluated using a similar procedure as given in 
section 4.3.2.1.2. 
 
4.3.5. Preparation of dipyridamole-loaded ADERT  
The dipyridamole-loaded ADERT was prepared i using similar procedure as 
given in section 4.3.2. with use of similar amount (40 mg) of quinidine sulfate as a model 
drug. 
 
4.3.4.1. Abuse deterrent potential of dipyridamole-loaded ADERT 
Abuse deterrent potential of dipyridamole-loaded ADERT was characterized in 
terms of using physical and chemical barrier studies. The physical barrier was evaluated 
using hardness testing using similar procedure as given in section 4.3.2.1.1.1. and 
chemical barrier was evaluated using a similar procedure as given in section 4.3.2.1.2. 
 
4.4. Effect of physical and/or chemical barrier on bilayer ADERT 
In addition to the physical barrier and/or chemical barrier as discussed in above 
sections, the bilayer ADERT served to provide the additional advantage as a chemical 
barrier. Bilayer ADERT was developed using pH modifying layer and extended release 
layer containing drug to evaluate deterrence to abuse via multiple unit oral ingestion.  
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4.4.1 Effect of alkalizing agent as a chemical barrier on propranolol HCl-
loaded bilayer ADERT 
Incorporation of alkalizing agent in ADERT may help to minimize drug release in 
case of multiple unit oral ingestion of ADERT. Propranolol HCl (pKa=9.5) was selected 
as a model drug, since it has a similar pKa value (9.1-9.5) to that of the opioids (Table 6). 
 
4.4.1.1. Preparation of propranolol HCl-loaded bilayer ADERT 
Bilayer ADERT was prepared by direct compression method, with two layers. 
Bilayer ADERT was designed to have a pH modifying layer (top layer), consisting of the 
alkalizing agent which would help to modify the pH of the dissolution medium, when 
multiple units were added to the medium. On the other hand, the  extended release layer 
(bottom layer) consisted of the propranolol HCl to achieve the  extended release effect for 
a prolonged period. 
 
4.4.1.1.1. pH modifying layer 
Magnesium hydroxide, aluminum hydroxide, calcium carbonate, and calcium 
hydroxide were used as an alkalizing agent. Kollidon CL-SF was used as a super 
disintegrant. The pH modifying layer contains an alkalizing agent, Kollidon CL-SF, 
magnesium stearate, and MCC KG-1000 at a ratio of 50:5:0.5:44.5 (Table 12). Powder 
mixture for the pH modifying layer was prepared by blending all the ingredients by dry 
mixing using mortar and pestle.
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4.4.1.1.2. Extended release layer 
Based on the results of various studies provided in section 4.3.2.1, formulation 
F12 was selected as an extended-release layer. The extended-release layer contained 
model drug, HPMC K100M, MCC KG-1000, and magnesium stearate at a ratio of 
8:30:61.5:0.5 (Table 12). The powder mixture of the extended-release layer was prepared 
by blending all the ingredients by dry mixing using mortar and pestle. Control 
formulation is a single layer ADERT contained similar composition as of an extended 
release layer. 
 
4.4.1.1.3. Preparation of bilayer ADERT 
Bilayer ADERT were compressed on a Carver Press using a 12 mm flat round set 
of die and punch tool. An illustration of the bilayer tableting process is shown in Figure 
5.  
Accurately weighed quantity of 500 mg powder (extended-release layer) was 
manually loaded into the die and compressed at a pressure, P1, of 200 lbs. to make the 
first tablet layer (Figure 5a). Without ejecting the first layer, 200 mg of a second powder 
(pH modifying layer) was again manually added to the die and the second (final) 
compression was carried out at P2, which was 2500 lbs. (Figure 5b). Finally, the bilayer 
tablet (ADERT) was ejected from the die by pushing the second layer downward with the 
punch (Figure 5c). Similarly, all other tablets were prepared.  
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4.4.1.2. Screening of alkalizing agent 
Various alkalizing agents such as magnesium hydroxide, aluminum hydroxide, 
calcium carbonate and calcium hydroxide were screened to determine their effect as a 
chemical barrier via multiple unit’s oral ingestion based on in-vitro drug release study. 
 
4.4.1.2.1. In-vitro drug release study 
4.4.1.2.1.1. Biorelevant dissolution media  
For the in-vitro drug release, bio-relevant media has been widely used to 
adequately predict the in-vivo behavior of drug formulations by adapting simulation of 
gastrointestinal conditions (41). Fasted state simulated gastric fluid (FaSSGF) and fasted 
state simulated intestinal fluid (FaSSIF) were used as bio-relevant media for the in-vitro 
dissolution test. FaSSGF was prepared by dissolving 80 mM of sodium taurocholate, 20 
mM of lecithin, 0.1 mg/mL of pepsin, and 34.2 mM of sodium chloride in distilled water. 
The pH of FaSSGF was adjusted to 1.6 with 6 N hydrochloric acid (HCl). FaSSIF was 
prepared by dissolving 3 mM of sodium taurocholate, 0.75 mM of lecithin, 3.438 g of 
sodium dihydrogen phosphate and 6.186 g of sodium chloride in 1 L of deionized water 
adjusted to pH 6.5 with 10 M sodium hydroxide (NaOH) solution (41). Double 
concentrated FaSSIF (2xFaSSIF) was obtained by using two times the amount of each 
ingredient of FaSSIF in deionized water, followed by adjusting pH to 6.5 with 10 M 
NaOH solution. 
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4.4.1.2.1.2. Protocol for in-vitro drug release 
In-vitro drug release study was carried out using the two-stage bio-relevant drug 
release method which represents the gastrointestinal transfer. The study was performed 
using USP dissolution apparatus 2 (rotating paddle) with a paddle speed of 100 rpm, at 37 
°C  0.5 C, using an initial volume of 250 mL for FaSSGF (pH 1.6) for 2 h. 
Subsequently, 250 mL of 2×FaSSIF (pH 6.5) was added to achieve a final volume of 500 
mL of FaSSIF. The pH of the final liquid in the dissolution vessel was adjusted to 6.5 
using a 10 M NaOH solution .(41) The dissolution test was performed for 24 h. pH of the 
dissolution vessel was measured at various time points using a pH meter. 
 
4.4.1.2.1.3. Single unit drug release 
The single unit drug release study was carried out for a control formulation 
(without a pH modifying layer) and a bilayer ADERT for all the formulations using the 
protocol mentioned in section 3.4.2. Aliquots (1 mL) were withdrawn at specific 
predetermined time intervals from the medium and filtered through a 0.45 μm syringe 
filter. At each time point, an equal volume of fresh bio-relevant media was added to the 
dissolution vessels. Drug content was determined by the HPLC method as described 
previously for propranolol HCl, quinidine sulfate, and dipyridamole. The in-vitro drug 
release study was conducted in triplicate 
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4.4.1.2.1.4. Multiple-unit drug release 
The in-vitro drug release study with multiple bilayer ADERT was carried out to 
evaluate deterrence to multi-dose abuse. This study was conducted by adding multiple 
bilayer ADERT (3-and 5-unit) in the dissolution vessel at a time. Further steps were 
conducted similar to the single unit drug release study.  
 
4.4.2. Abuse deterrent potential of propranolol HCl-loaded bilayer ADERT 
4.4.2.1. Physical and chemical barrier 
Abuse deterrent potential of propranolol HCl-loaded bilayer ADERT was 
characterized in terms of physical and chemical barrier studies. Physical barrier was 
evaluated using hardness testing, by using similar procedure as given in section 
4.3.2.1.1.1. Chemical barrier was evaluated by drug extraction study on the intact tablet 
to evaluate drug extraction in water, 10%, and 40% ethanol, respectively. It was 
evaluated using similar procedure as given in section 4.3.2.1.2. pH of the drug extraction 
media was also determined at the end of the study. 
 
4.4.2.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of propranolol HCl-loaded bilayer ADERT 
To minimize drug release upon multiple-unit ingestion (3-and 5-tablet) in both 
FaSSGF and FaSSIF, additional alkalizing agent (i.e., magnesium hydroxide) was 
incorporated in the extended-release layer (Table 13) which will not only raise the 
microenvironmental pH (i.e., pH at the diffusion layer surface), but also increase bulk 
media pH upon multiple unit abuse. This increased pH can lead to decreased solubility of 
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weakly basic drug and thereby hindering drug release. To achieve this shift in 
microenvironmental and/or bulk pH of the media, various amount of magnesium 
hydroxide (25, 50, and 75 mg) was added to the extended release layer (Table 13) and 
drug release study was performed for single, 3-and 5-unit bilayer ADERT using 
propranolol HCl as a model drug using similar method outlined in section 4.4.1.2.1 
 
4.4.3 Effect of alkalizing agent as a chemical barrier on quinidine sulfate-
loaded bilayer ADERT 
Quinidine sulfate was selected as a model drug due to its similar pKa (8.1-8.7) as 
most opioids (Table 6). The bilayer ADERT containing quinidine sulfate was prepared 
according to Table 14, using similar method provided in section 4.4.1.1.  
 
4.4.4. Abuse deterrent potential of quinidine sulfate-loaded bilayer ADERT 
4.4.4.1. Physical and chemical barrier 
Abuse deterrent potential of quinidine sulfate-loaded bilayer ADERT was 
characterized using physical and chemical barrier studies. Physical barrier was evaluated 
using hardness testing using similar procedure as given in section 4.3.2.1.1.1. Chemical 
barrier was determined by drug extraction study performed on the intact tablet to evaluate 
drug extraction in water, 10%, and 40% ethanol, respectively. It was evaluated using 
similar procedure as given in section 4.3.2.1.2. pH of the drug extraction media was also 
determined at the end of the study. 
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4.4.4.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of quinidine sulfate-loaded bilayer ADERT 
To minimize drug release upon multiple unit ingestion, magnesium hydroxide 
was incorporated to the extended release layer (Table 15). The drug release studies of 
single and multiple units ADERT were performed using similar method outlined in 
section 4.4.1.2.1. 
 
4.4.5 Effect of alkalizing agent as a chemical barrier on dipyridamole-loaded 
bilayer ADERT 
Dipyridamole was selected as a model drug due to its similar pKa (6.5-7.1) to that 
of the opioids (Table 6). The bilayer ADERT containing quinidine sulfate was prepared 
according to Table 14, prepared similar to the method outlined in section 4.4.1.1.  
 
4.4.6. Abuse deterrent potential of dipyridamole-loaded bilayer ADERT 
4.4.6.1. Physical and chemical barrier  
Abuse deterrent potential of dipyridamole-loaded bilayer ADERT was 
characterized using physical and chemical barrier studies. Physical barrier was evaluated 
using hardness testing using similar procedure as given in section 4.3.2.1.1.1. Chemical 
barrier was determined by drug extraction study performed on the intact tablet to evaluate 
drug extraction in water, 10%, and 40% ethanol, respectively. It was evaluated using 
similar procedure as outlined in section 4.3.2.1.2. pH of the drug extraction media was 
also determined at the end of the study.  
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4.4.6.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of dipyridamole-loaded bilayer ADERT 
To minimize drug release upon multiple unit ingestion, in-vitro drug release 
studies of single and multiple units ADERT were performed using similar method as 
outlined in section 4.4.1.2.1. 
 
4.5. Correlation of effect of pH and drug release  
To correlate the effect of magnesium hydroxide on drug release and drug 
extraction, solubility of various model drugs at various pH were determined. 
Microenvironmental pH of various formulations were determined in water, FaSSGF and 
FaSSIF.  
 
Further, based on Noyes-Whitney equation (Equation 2), the drug release from 
the matrix tablet was mainly controlled by concentration of the drug at solid-liquid 
interphase (diffusion layer) (Cs), concentration of the drug in the bulk media (C) and 






 (𝐶𝑠 − 𝐶) 
Equation 2 
where, D is the diffusion coefficient of the solute in solution, S is the surface area of the 
exposed solid, h is the thickness of the diffusion layer, Cs is the solubility of the solid 
(i.e., concentration of a saturated solution of the compound at the surface of the solid and 
at the temperature of the experiment), and C is the concentration of solute in the bulk 
solution and at time t. The quantity dC/dt is the dissolution rate, and V is the volume of 
solution (42).
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4.5.1. Determination of pH solubility of various model drugs  
Solubility of various model drugs were determined over a pH range of 1.6–10.5. 
To avoid pH fluctuation during the experiments, an excess of model drug was added to 
the following solvent, respectively: acid phthalate buffer (pH 1.6–4), neutralized 
phthalate buffer (pH 4–5.8), phosphate buffer (pH 5.8–8.0), borate buffer (pH 8.0-10.5), 
10% ethanol, and 40% ethanol. After equilibrating on shaker water bath (37 ± 1 °C) for 
24 h, samples were filtered through 0.45 μm filter and the drug concentration in filtrate 
was determined by HPLC method. For comparison with theoretical values at various pH, 
an equation based on the pKa and intrinsic solubility of the drug was used. 
 S
So
= (10pKa−pH) + 1 Equation 3 
where, S and So are solubility at test pH and at any pH above pKa, respectively. The 
value of So was determined experimentally at pH 10.5 for all model drug (39). 
 
From Equation 3, the pH solubility profile of a weakly basic drug (opioid) can be 
predicted. Based on the pH-solubility of an opioid, drug release at higher pH values can 
be expected to be reduced due to reduction in the solubility. Since the pKa of the model 
drug is similar, similar pH-solubility profile may be expected to that of an opioid. 
According to this consideration, during the drug release of multiple unit bilayer ADERT, 
both bulk media, and microenvironmental pH increase, owing to the effect of alkalizing 
agent. This can lead to a reduction in the solubility of the drug and hence leading to a 
reduction in the drug release. Based on this, it can be assumed that drug release profile(s) 
with multiple unit ADERT prepared with model drug(s), may be similar to drug release 
profile as that of the opioid.
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4.5.2. Estimation of microenvironmental pH of ADERT powder blend 
prepared using various model drugs 
The microenvironmental pH of a drug-excipient blend for various formulations 
was estimated by adding 10 mL of various solvents (water, FaSSGF, and FaSSIF) to 400 
mg of blend in a vial, mixing the suspension with a vortex mixer, and then recording the 
pH with a pH meter (43). With increase in the amount of alkalizing agent in the 
extended-release layer can lead to an increase in the microenvironmental pH, that will 
help to reduce drug release when multiple units ADERT ingested. This was based on the 
assumption that with multiple unit ADERT, since the amount of alkalizing agent will 
increase leading to an increase in both microenvironmental pH and bulk media pH under 
drug release study. At higher pH, the reduction in the solubility of weakly basic drug may 
lead to reduction in the drug release upon multiple unit ingestion. 
 
4.6. Statistical analysis 
To confirm statistically significant difference the statistical tool ANOVA 
(analysis of variance) and/or t-test was applied wherever applicable, considering 
appropriate parameter for comparison at an α value of formulations p<0.05, 0.01, 0.001, 
and 0.0001, respectively.
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5. RESULTS AND DISCUSSION  
5.1. Effect of excipients as physical barrier on ADERT 
 Abuse deterrent potential of various polymers were evaluated by determining 
their effect as a physical barrier by following studies. 
 
5.1.1. Effect of polymers as physical barrier to screen of type of polymer  
Various hydrophilic polymers were selected to screen type of polymer through 
their effect as a physical barrier by evaluation of following studies. 
 
5.1.1.1. Swelling behaviors of polymers 
Abusers use commonly available solvents to dissolve crushed tablets, making it 
suitable for parenteral route, also make a concentrated solution of the dissolved tablet to 
abuse via oral route. From Table 5 it was observed that methyl cellulose, Carbopol 907, 
Carbopol 940, methyl cellulose PEO 5M, PEO 7M, HPMC K15M, and HPMC K100M 
dissolved slowly and swelled in all the solvents used. The swelling of polymers in 
various solvents was attributed to diffusion of the solvent into the polymer molecule 
which leads to plasticization of the polymer by the solvent. This plasticization leads to 
formation of a gel-like swollen layer along with two separate interfaces, one between the 
glassy polymer and gel layer; and other between the gel layer and the solvent. The 
polymer dissolves after the induction time (time required for polymer to dissolve) since, 
hydration of polymer takes certain period and that is directly proportional to the 
molecular weight of polymers (43). 
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Also, being nonionic nature of methyl cellulose PEO 5M, PEO 7M, HPMC 
K15M, and HPMC K100M helps swelling of these polymers in various solvent. Whereas, 
chitosan showed dissolution/swelling only in 0.1N HCl (acidic environment). In acidic 
conditions, amino groups of chitosan can be partially protonated resulting in repulsion 
between positively charged macro chains, thereby allowing diffusion of water molecules 
and subsequent solvation of macromolecules (43). Also, due to its semi crystalline nature, 
derived mainly from inter- and intra-molecular hydrogen bonds, chitosan is water-soluble 
only at acidic pH environment (44,45). Locust bean gum, xanthan gum, corn starch, and 
gelrite gum did not swell/dissolve in 0.1N HCl. These are natural polymers that are 
anionic in nature (46). Being anionic polymers, they have reduced solubility at a pH 
value lower than their pKa. Abusers use commonly available solvents to dissolve crushed 
tablets, making it suitable for parenteral administration, they also make a concentrated 
solution of the dissolved tablet to abuse via oral route. To minimize the abuse, the tablets 
prepared with polymers (i.e., methyl cellulose, Carbopol 907, Carbopol 940, PEO 5M, 
PEO 7M, HPMC K15M, and HPMC K100M) that dissolve and swell in all the 
commonly available solvents were selected for further studies.  
 
5.1.1.2. Viscosity study  
The viscosity profile of selected polymeric solutions in various solvents are 
displayed in Figures 6-10. From Figure 6, it was observed that viscosity of polymeric 
solutions in water decreases as the with increase in spindle speed at various rpm (rotation 
per minute) increases. This could be attributed to the shear thinning property of the 
polymeric solution. The shear thinning property refers to the decrease in the viscosity of a 
 40 
polymeric solution with increase in the applied shear rate, and the polymeric solution is 
called a pseudoplastic fluid (46).A portion of a curve from Figure 6 was enlarged in the 
same figure window at higher rpm (20-100 rpm), and the values of viscosity of polymers 
at 100 rpm was given in Table 7. From Table 1, it was observed that HPMC K100M 
showed significantly higher viscosity as compared to all the polymer used in the study (p 
> 0.05 as compared using ANOVA test). This may be observed due to the higher 
molecular weight of HPMC, since the action of HPMC on liquid uptake depends on the 
molecular weight. It has been reported that HPMC of a higher molecular weight has a 
greater liquid uptake capacity that leads to increase in viscosity of HPMC K100M (46). 
 
Pseudoplastic behavior was observed for all the polymers in 10% ethanol, 40% 
ethanol, 0.1N HCl, and 70% isopropanol (Figure 7-10). From Figure 7,8 and 10, it was 
observed that viscosity of the polymers in hydroalcoholic solvent increases compared to 
water. This could be due to the decreased dielectric constant of the hydroalcoholic 
solutions owing to reduction in the volume of water in the hydroalcoholic solvent. This 
may have prompted the development of new bonds/structures between the polymer 
molecules and the solvating media as reported (47). On the other hand, increased ethanol 
content in the media could have led to formation of stronger gels. The interactions of the 
polymer solvated by the ethanol were far more prominent than the interactions of the 
polymer with water because of hydrogen holding and van der waal forces between the 
ethanol and polymer (48). 
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Also, HPMC K100M showed significantly higher viscosity compared to other 
polymers in all the solvents (Table 7). From Figure 9, it was observed that viscosity of all 
the polymers were reduced in 0.1N HCl compared to other solvents used. This was 
observed due to conversion of acidic group present on the polymers into protonated acid 
and that lead to reduction in swelling of the polymers under acidic environment. 
Viscosity of Carbopol 940 and 71G has not been reported in Figure 9, because viscosity 
was not detected due to limited torque generation with similar experimental conditions.  
 
Since HPMC K100M showed higher viscosity compared to other polymers at 
higher rpm, it was selected for further studies. HPMC K100M was also compared with 
polyethylene oxide (PEO 7M), since PEO 7M has been widely used for abuse-deterrent 
formulations. 
 
5.1.1.3. Heat induced viscosity study  
Based on the results of heat-induced viscosity study as shown in Figure 11, the 
viscosity of HPMC K100M was observed to be significantly higher as compared to PEO 
7M at various temperatures studied (p > 0.05 as compared using t-test). Also, it was 
observed that the viscosity of both polymeric solutions at 100 rpm was reduced with 
increase in temperature. This was observed due to molecular rearrangement in polymeric 
solutions at higher temperature. To initiate flow of a polymeric solution, energy (Ea) is 
required to break bonds in liquids composed of molecules that are associated through 
hydrogen bonds. These bonds are broken at higher temperatures by thermal movement 
and leads to decrease in viscosity and increase in flowability. 
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Ea values of HPMC K100 M and PEO 7M solutions were observed to be 4906 
cal/mole and 1646 cal/mole at 100 rpm, respectively. This indicates that HPMC K100 M 
solution requires higher activation energy to initiate flow property. In other words, 
HPMC K100M would require more force to be withdrawn from a syringe.  
 
5.1.1.4. Syringe-ability study  
Figure 12 represents the syringe-ability profile which was plotted based on the 
data as shown in  Table 8, respectively. Based on Table 8, syringe-able force of 2% w/v 
polymeric solution of HPMC K100M and PEO 7M in water was found to be 14.6  0.7 N 
and 13.5  2.0 N, respectively (displayed in Figure 12 on positive y-axes). In 10% 
ethanol, the syringe-ability was found to be 15.5  1.0 N, 13.3  0.9 N, and in 40% 
ethanol, the syringe-ability was found to be 16.1  0.3 N, 14.7  1.2 N for HPMC 
K100M and PEO 7M, respectively. Also, the syringe-able force increased with 10% and 
40% ethanol compared to water. It was observed due to increase in viscosity of the given 
polymers in hydroalcoholic solvent (observed from section 5.1.1.2.), which have more 
swelling capacity in hydroalcoholic solvent and thus requires higher force to be 
withdrawn by a syringe (i.e., provides higher resistance to syringe-ability). The syringe-
able force for HPMC K100M was higher in all the solvents to that of PEO 7M and that 
indicates HPMC K100M may provide a stronger physical barrier as compared to PEO 
7M.  
 
Additionally, as given in Figure 12, the intercept of the curve on negative x-axes 
represents the volume of solution withdrawn into the syringe through the needle and 
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values of the volume withdrawn is given in Table 8. It was observed that PEO 7M was 
syringe-able among all the polymeric solution into the syringe. Whereas, HPMC K100M 
solution could not be withdrawn into a syringe. Based on this, 2%w/v polymeric solution 
of HPMC K100M act as a better polymer with physical barrier characteristics compared 
to PEO 7M. Furthermore, these two polymers were used to prepare abuse deterrent 
extended release tablet with various type of diluent.  
 
5.1.2. Abuse deterrent potential of metformin HCl ADERT  
Abuse deterrent potential of prepared ADERT was characterized using physical 
and chemical barrier studies.  
 
5.1.2.1 Physical barrier: Screening of type of diluent  
Physical barrier of metformin ADERT was characterized by evaluation of 
Hardness and syringe-ability studies.  
 
5.1.2.1.1 Hardness testing 
Hardness of the formulations F1-F12 are displayed in Table 9. Hardness of all the 
formulations was found to be more than 30 kg. This was attributed to the presence of 
high molecular weight polymers (PEO 7M or HPMC K100M) in higher amount (150 mg) 
which act as binders, respectively. As per Table 9, tablet hardness was found to be higher 
in the formulations F5, F6, F11, and F12, where MCC KG-802 and KG-1000 were used 
as diluent, respectively. This might be attributed to the needle shape of these novel MCC 
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grades, which leads to high compression characteristics with lower elastic recovery and 
makes tablet with higher hardness. 
 
5.1.2.1.2. Syringe-ability study 
Figure 13 represents the syringe-ability profile which was plotted based on the 
data as shown in  Table 10, respectively. Based on Table 10, syringe-able force of 
formulations F7-F12 that contains HPMC K100M was higher (16-20 N) compared to 
formulation F1-F6 (14-16 N) that contains PEO 7M, and it was increased for all the 
formulations in hydroalcoholic solvents (10%, and 40% ethanol) compared to water. 
Both of these observations can be correlated to the viscosity study in which solution of  
HPMC K100M have higher viscosity compared to PEO 7M solution, and due to increase 
in swelling capacity of the polymer in hydroalcoholic solvent, it requires higher force to 
be withdrawn by the syringe. Also, it was observed that similar force was required for 
formulation F1-F6 and F7-F12 in same solvent. For example, syringe-able force for 
formulation F1-F6 was found to be around 14 N in water, 14.5 N in 10% ethanol, and 15 
N in 40% ethanol. From the data, it was observed that the effect of type of diluent 
(various type of MCC) has minimum and/or similar impact on syringe-able force.  
 
Corresponding volumes withdrawn (Table 10) during syringe-ability test were 
found in the range of 1-3.5 mL for formulation F1-F6, and it was less than 1 mL for 
formulation F7-F12 in all the solvent used. This data corelates to the syringe-ability data 
(as given is section 5.1.1.4.) for polymeric solutions of HPMC K100M and PEO 7M, 
where it was found that PEO 7M polymeric solution was more syringe-able as compared 
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to HPMC K100M. This explains that upon mechanical manipulation of tablets (crushing) 
and dissolving the powder in various solvents, it would form a gel resulting in difficulty 
to be withdrawn from the syringe when formulations contain HPMC K100M.  
 
5.1.2.2. Chemical barrier: Drug extraction study 
Results for drug extractions are displayed in Figure 14 and Table 11. The 
viscosity and syringe-ability studies of polymeric solutions (PEO 7M and HPMC 
K100M) can be correlated with the type of solvent used for drug extraction. For instance, 
increasing alcohol content (i.e., from 10% to 40%) in the solvent resulted in decreased 
drug extraction from all formulations (Table 11) as compared to water. As the viscosity 
of these polymers increases in presence of 10% and 40% ethanol, swelling of polymer 
increases, respectively. The swollen polymer retards drug diffusion from the polymeric 
matrix and subsequently reduces drug extraction.  
 
The drug extraction study suggests that both HPMC K100M and PEO 7M have 
the potential to provide a chemical barrier to minimize extraction in various solvents. 
However, addition of novel type of diluent, i.e., KG-1000 grades to the formulation 
(formulation F6 and F12, respectively) increases the hardness of the tablet and leads to 
reduction in the pores on the surface of a tablet and that results in reduction of drug 
diffusion and thereby drug extraction (Table 11). 
 
Note: Based on the screening viscosity, syringe-ability, and tablet hardness, and 
drug extraction studies, it was observed that HPMC K100M could provide better physical 
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and/or chemical barriers as compared to PEO 7M. Also, MCC KG-1000 grade serves as a 
better diluent to increase the mechanical strength of tablets (Formulation F12). Hence, 
Formulation F12 was selected for their abuse deterrent potential with use of various type 
of model drugs.  
 
5.1.3. Abuse deterrent potential of propranolol HCl ADERT  
Abuse deterrent potential of propranolol HCl ADERT was characterized using 
hardness testing as a physical barrier and drug extraction study as a chemical barrier 
study. Hardness of the propranolol HCl ADERT (Formulation P) was found to be 45.7   
0.6 kg, which is similar to formulation F12. Drug extraction study of formulation P is 
displayed in Figure 15. The drug extraction of Formulation P showed similar trend to that 
of formulation F12.  
 
The hardness and drug extraction were similar for formulation P and F12 since 
the polymeric matrix are similar. The only difference between formulation P and F12 is 
the drug, and based on Equation 3, drug solubility is the only parameter that modifies the 
diffusion of the drug. Propranolol HCl is freely soluble at ~pH 7 of the drug extraction 
media (Figure 19B). Drug extraction was reduced despite high solubility of drug in 
hydroalcoholic media (189  9 mg/mL in 10% ethanol and 232  11 mg/mL in 40% 
ethanol) due to presence of swollen polymer which retards drug diffusion.  
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5.1.4. Abuse deterrent potential of quinidine sulfate ADERT  
Abuse deterrent potential of quinidine sulfate ADERT was characterized using 
hardness testing as a physical barrier and drug extraction study as a chemical barrier 
study. Hardness of the quinidine sulfate ADERT (Formulation Q) was found to be 44.5   
0.9 kg. Drug extraction of formulation Q was found to be similar to formulation P (Figure 
15). pH of extraction media was found to be around 7, drug solubility is 6.4  0.2 mg/mL 
at pH 7.1(Figure 27). The solubility of quinidine sulfate in 10% ethanol and 40% ethanol 
was found to be 44  2 mg/mL and 112  8 mg/mL, respectively. The reduced drug 
extraction in hydroalcoholic solvent was due to higher swelling of polymer in the media.  
 
5.1.5. Abuse deterrent potential of dipyridamole ADERT  
Abuse deterrent potential of dipyridamole ADERT was characterized using 
hardness testing as a physical barrier and drug extraction study as a chemical barrier 
study. Hardness of the dipyridamole ADERT (Formulation D) was found to be 44.6  0.6 
kg. As shown in Figure 15, the drug extraction of dipyridamole in water was found to be 
significantly lower as compared to formulation P and Q. This was observed due to poor 
solubility of the drug at pH 7, i.e. 0.04 mg/mL (Figure 35). However, the drug extraction 
of dipyridamole in hydroalcoholic media was similar to formulations P and Q. The 
solubility was found to be 39  2 mg/mL and 53  3 mg/mL in 10% ethanol and 40% 
ethanol, respectively. 
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5.2. Effect of physical and/or chemical barrier on bilayer ADERT 
Propranolol HCl (pKa 9.5), quinidine sulfate (pKa 8.5), and dipyridamole (pKa 
6.4) loaded bilayer abuse deterrent extended release tablet of were prepared along with 
alkalizing agent, respectively, to determine their abuse deterrent potential as a chemical 
barrier. 
 
5.2.1 Effect of alkalizing agent as a chemical barrier on propranolol HCl-
loaded bilayer ADERT 
Propranolol HCl-loaded bilayer abuse-deterrent extended-release tablets 
(ADERT) were prepared to screen type of alkalizing agent (Table 12). 
 
5.2.1.1 Screening of alkalizing agent 
The alkalizing agent was screened based on  in-vitro drug release study of 
formulation P1-P4 were carried out in in FaSSGF for 2 hours  followed by FaSSIF for 
additional 22 hours for single unit as well as and multiple units. The drug release profiles, 
and pH of the release media during drug release are depicted in Figure 16 and 19, 
respectively. Based on Figure 16, it was observed that the drug release of the formulation 
P1-P4 was found to be similar to the control formulation for 1, 3, and 5 unit, respectively. 
No reduction in drug release was observed upon multiple unit drug release study. It was 
observed due to minimal shift in bulk media pH (Figure 19), and drug solubility was not 
altered at this pH of the media (i.e., pH of the intestinal media was found to be in a range 
of 6.5 to 6.8, and the drug solubility of propranolol HCl observed at pH 6.8 was 
 49 
69.33±2.50 mg/mL). Due to higher solubility of the drug, no reduction in drug release 
was observed upon multiple unit release study.  
 
The first two hours of the two-stage drug release study reflect the release in 
FaSSGF of pH 1.6, and the amount of drug released at the end of two hours is 
represented in Figure 19. In this acidic environment 13.67±1.62 mg of the drug was 
released after 2 hours from the control ADERT. Based on Equation 2, the drug release 
from the matrix tablet was majorly controlled by the concentration of the drug at the 
solid-liquid interphase (diffusion layer) (Cs), concentration of the drug in the bulk media 
(C) and diffusivity of the drug from polymeric matrix (D) in the bulk media. The pH of 
the media after two hours was found to be 1.64±0.08 (Figure 19) and the solubility of 
propranolol HCl at this pH 183.8±3.7 mg/mL (Figure 20). Based on solubility data, the 
drug is freely solubilized in the acidic environment, and thereby the drug release should 
not be hindered by the solubility of the drug. However, the limited drug release (i.e. 
32.7±1.9%) in FaSSGF was attributed to the presence of high molecular weight HPMC 
K100M as a release rate controlling polymer. HPMC K100M swells in the media and 
releases the drug in a controlled manner by slow diffusion from the polymeric matrix.  
 
Similarly, drug release from single unit bilayer ADERT from formulation P1 
reflected similar drug release in FaSSGF after the initial two hours (13.10±0.78 mg). The 
pH modifying layer containing MgOH2 disintegrated quickly (within 30 seconds) once 
the bilayer ADERT came in contact with the FaSSGF. The pH of the media was found to 
be 1.92±0.10 after two hours. There was a minimal shift in pH in dissolution media from 
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single bilayer ADERT to that of the control tablet. This was attributed to the presence of 
a large quantity of FaSSGF (250 mL) and a limited amount of MgOH2 (100 mg) that is 
not sufficient to shift the pH of the media. Also, the release profile of formulation P1 in 
FaSSIF was similar to the control ADERT, due to the similar composition of ingredients 
in the extended-release layer. Hence, the drug release controlled majorly by the rate-
controlling polymer HPMC K100 M in the FaSSIF as well.  
 
To evaluate multidose oral abuse, the drug release study was performed by 
placing multiple unit bilayer ADERT (3-and 5-unit) at once in the dissolution vessel. 
Based on Figure 19, the drug release from 3 unit and 5 units of formulation P1 after two 
hours were found to be 36.76±5.18 mg and 46.95±5.0 mg, respectively. Also, based on 
Figure 19 A, the pH of the media was raised to 5.45±0.78 and 9.42±0.49 after two hours 
when 3- and 5-unit bilayer ADERT were studied, respectively. This increase in pH was 
due to the presence of a higher amount of MgOH2 in the dissolution vessel, which is 
sufficient to shift to higher pH. Drug release from 3 units was found to be similar to the 
3-unit control formulation ADERT, and drug release did not decrease even when a higher 
amount of alkalizing agent (300 mg of MgOH2) was available to modify pH of the media. 
This was attributed to solubility of drug at pH 5.45 that is 126.3±5.4 mg/mL, drug release 
did not decrease as there was presence of sufficient media for complete dissolution of the 
drug that was released from the ADERT. However, drug release from 5-unit bilayer 
ADERT of formulation P1 was reduced significantly compared to control formulation. 
This reduction in the drug release was attributed to reduced solubility (0.72±0.02 mg/mL) 
of the drug at increased pH of the dissolution medium (pH of 9.4). 
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As represented in Figure 20, no significant reduction in the drug release was 
observed for formulation P2, P3, and P4 compared to control ADERT for single and 
multiple unit ADERT in the FaSSGF. This was attributed to pH shift of the bulk media, 
none of the alkalizing agents (aluminum hydroxide, calcium carbonate, and calcium 
hydroxide) raised pH more than 6.5 after 2 hours (Figure 19). Moreover, the solubility of 
the drug was found to be 83.0±2.1 mg/mL at pH 6.5 and due to high solubility of the 
drug, the drug release did not decrease in FaSSGF for formulation P2, P3, and P4 for 
both single as well as multiple unit bilayer ADERT drug release study.  
 
Magnesium hydroxide was selected as an alkalizing agent for further studies, 
since it shifts pH of media from acidic (pH 1.6) to alkaline (pH 9.2) form drug release 
studies in FaSSGF compared to aluminum hydroxide, calcium carbonate, and calcium 
hydroxide. Since MgOH2 can increase bulk media pH up to 9.2 with multiple unit drug 
release study, it has the potential to act as a chemical barrier that will reduce the 
solubility of weakly basic drugs. 
 
5.2.2 Abuse deterrent potential of propranolol HCl-loaded bilayer ADERT 
5.2.2.1. Physical and chemical barrier 
Abuse deterrent potential of propranolol HCl-loaded bilayer ADERT was 
characterized using hardness testing as a physical barrier and drug extraction study as a 
chemical barrier study. Hardness of the formulations P1, P2, P3, and P4 was found to be 
46.18   0.37, 46.56   0.94, 47.51   0.82, and 46.06   1.22 kg, respectively. The 
hardness was similar to  the control formulation (formulation P) since MCC KG1000 as a 
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diluent was used in pH modifying layer and similar compression pressure (2500 lbs) was 
used to prepare bilayer tablet. 
 
Drug extraction of formulation P1-P4 and their comparison with control 
formulation (Formulation P) is presented in Figure 20. Based on Figure 20 A, it was 
observed that the drug extraction of formulations P1-P4 was reduced significantly (less 
than 1 mg extracted) compared to the control formulation in all solvents. This was 
observed due to presence of alkalizing agents in all the formulations, the bilayer ADERT 
disintegrate and raises the pH of the extraction media (Figure 19 B). Solubility of the 
drug decreases at higher pH (Figure 20) which leads to reduction in drug extraction in 
water. Also, drug extraction from P1-P4 was found to be reduced in hydroalcoholic 
solvents compared to control formulation, due to increased pH of the extraction media 
and increased swelling of polymers in hydroalcoholic solvents resulting in reduction in 
rug extraction.  
 
5.2.2.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of propranolol HCl-loaded bilayer ADERT 
Magnesium hydroxide was incorporated in extended-release layer to minimize 
drug release upon multiple-unit ingestion (3- or 5-tablet) in both FaSSGF and FaSSIF. 
Formulations P25, P50, and P75 with various amount of magnesium hydroxide (Table 
13) were developed and hardness was found to be 45.21   0.53, 44.15   0.75, and 44.55 
 0.80 kg for formulations P25, P50, and P75, respectively. Drug extraction of 
formulation P25, P50, and P75 was not performed due to presence of similar pH 
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modifying layer as that of formulation P1. Similar pH modifying layer may lead to 
similar (increased) pH of the extraction media and the drug extraction can be predicted 
based on the solubility of the drug at higher pH (from Equation 3) and which leads to 
reduction in diffusion of the drug. Hence, based on the pH values found in Figure 19 B, 
the drug extraction would be found similar for formulations P25, P50, and P75 as 
formulation P1. 
 
Drug release from single unit bilayer ADERT is presented in Figure 22. The drug 
release profiles from formulation P25, P50, and P75 were found to be of similar to the 
control formulation and formulation P1. However, with increase in the amount of 
magnesium hydroxide in the extended release layer (formulations P25, P50, and P75) the 
amount of propranolol HCl released was decreased compared to control formulations. 
This was due to presence of magnesium hydroxide which leads to increase in 
microenvironmental pH of formulations P25, P50, and P75 compared to control 
formulation. Based on the results from Table 16, the microenvironmental pH for the 
control formulation was found to be 5.56±0.05, 2.85±0.14, and 6.57±0.04 in water, 
FaSSGF, and FaSSIF, respectively. On the other hand, the values of microenvironmental 
pH were around 8, 8.4, and 9 for formulations P25, P50, and P75, respectively, in both 
FaSSGF and FaSSIF (Table 16). Hence, due to increased microenvironmental pH, 
diffusion of the drug from polymeric matrix reduced slightly from formulations P25, P50, 
and P75, respectively compared to control formulation.  
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In-vitro drug release profiles from single and multiple-unit of propranolol HCl-
loaded bilayer ADERT of formulation P25, P50, and P75 in FaSSGF for 2 hours 
followed by FaSSIF for additional 22 hours and their comparison with control 
formulation are presented in Figure 26. Significant reduction in propranolol HCl release 
from multiple-unit (3- and 5-tablets) of formulations P25, P50, and P75 compared to 
multiple-unit of control formulation was observed. In addition, from Figure 26A, it was 
observed that increasing the amount of magnesium hydroxide in the extended release 
layer, the amount of propranolol HCl released at 2 hours in FaSSGF was decreased 
compared to control formulations. Similar results were observed during the additional 22 
hours in FaSSIF (Figure 26B). 
 
This reduction in drug release was due to an increase in both microenvironmental 
pH and bulk media pH which leads to reduction in solubility of propranolol HCl. The 
values of microenvironmental pH were 8, 8.4, and 9 for formulations P25, P50, and P75, 
respectively, in both FaSSGF and FaSSIF (Table 16). pH in bulk media with 3-unit 
bilayer ADERT were 8.7, 8.9, and 9.1, respectively, from formulations P25, P50, and P75 
in FaSSGF at 2 hours and 7.8, 8.1, and 8.6 in FaSSIF at additional 22 hours (Figure 27). 
Also, the values of pH with 5-unit bilayer ADERT were 9.3, 9.35, and 9.4, respectively, 
from formulations P25, P50, and P75 in FaSSGF at 2 hours and 8.6, 8.8, and 9.2 in 
FaSSIF at additional 22 hours (Figure 27).  
 
Hence, based on Equation 3, the changes of pH led to reduction in solubility of 
drug (Figure 21) which leads to reduction in the diffusion of the drug from the various 
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ADERT formulations. Thus, by change in microenvironmental pH as well as bulk media 
pH, the drug release can be reduced significantly upon multiple unit drug release study 
compared to control formulation ADERT. Thus, administering multiple-unit ADERT of 
formulations P25, P50, and P75 formulated with an opioid drug with pKa of 9.5 (like 
propranolol HCl) might lead to a reduction in euphoric effect of opioids.  
 
5.2.3 Effect of alkalizing agent as a chemical barrier on quinidine sulfate-
loaded bilayer ADERT 
In-vitro drug release study of quinidine sulfate loaded bilayer ADERT was 
determined. The in-vitro drug release profiles from quinidine sulfate-loaded bilayer 
ADERT were found to be similar to that of propranolol HCl-loaded bilayer ADERT. 
From Figure 28, it was observed that drug release profile of formulation Q1 was similar 
to control formulation for 1 and 3-unit ADERT. The drug release profile for 5-unit 
bilayer ADERT of formulation Q1, was significantly less compared to 5-unit control 
formulation (Figure 28). This reduced drug release in FaSSGF was attributed to increased 
bulk media pH from 1.6 to 9.21±0.6 (Figure 37) and solubility of quinidine sulfate was 
reduced to 0.25±0.02 mg/mL at pH 9.2 (Figure 31). Hence, due to reduction in solubility 
of the drug reduces drug diffusion from the polymeric matrix. However, drug release 
from 5-unit bilayer ADERT of formulation Q1 was not reduced in FaSSIF. This was 
attributed to pH of the bulk media which remained around pH 6.9 (Figure 37) and the 
solubility of quinidine sulfate was found to be 9.15±0.18 mg/mL (Figure 31) at this pH. 
Due to this high solubility of the drug, drug release was found to be similar for 5-unit 
ADERT of both control and Q1 formulation s in FaSSIF. 
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5.2.4. Abuse deterrent potential of quinidine sulfate-loaded bilayer ADERT 
5.2.4.1. Physical and chemical barrier 
Abuse deterrent potential of quinidine sulfate-loaded bilayer ADERT was 
characterized using hardness testing as a physical barrier and drug extraction study as a 
chemical barrier study. Hardness of the formulations Q1 was found to be 46.80  0.80 kg. 
 
Drug extraction of formulation Q1 was found to be similar to formulation P1. 
Drug extraction of formulation Q1 and their comparison with control formulation 
(Formulation Q) is presented in Figure 26. Based on Figure 30 A, it was observed that the 
drug extraction of formulation Q1 was reduced significantly (less than 1 mg extracted) 
compared to control formulation in all the solvents. This was observed due to presence of 
magnesium hydroxide in all the formulations which raises the pH of the extraction media 
(Figure 30 B). Solubility of the drug decreases at higher pH (Figure 37)which leads to 
reduction in drug extraction in water.  
 
5.2.4.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of quinidine sulfate-loaded bilayer ADERT 
Similar to propranolol HCl-loaded bilayer ADERT, to minimize drug release for 
multiple unit (3-and 5-unit) study, various amounts of magnesium hydroxide were added 
to extended release layer of the bilayer ADERT (Table 15). Hardness of the formulations 




From Figure 32, similar trend in drug release profiles were observed for single 
unit ADERT of various formulations Q25, Q50, and Q75 to that control formulation, and 
drug release was found to be similar for single unit formulations containing propranolol 
HCl (P25, P50, and P75). From Figure 32, a slight reduction in drug release with 
increased amount of magnesium hydroxide in the formulations was observed. This 
reduced drug release was due to increase in microenvironment pH. The values of 
microenvironmental pH were around 7.9, 8.4, and 9.3 for formulations Q25, Q50, and 
Q75, respectively, in both FaSSGF and FaSSIF (Table 16) and due to increased 
microenvironmental pH, the diffusion of the drug from polymeric matrix was reduced 
slightly from formulations Q25, Q50, and Q75, respectively compared to control 
formulation.  
 
In-vitro drug release profiles from single and multiple-unit of propranolol HCl-
loaded bilayer ADERT of formulation Q25, Q50, and Q75 in FaSSGF for 2 hours 
followed by FaSSIF for additional 22 hours and their comparison with control 
formulation are presented in Figure 34. Similar to the formulations prepared with 
propranolol HCl, there was significant reduction in release profiles from multiple-unit (3- 
and 5-unit) of formulations Q25, Q50, and Q75 as compared to multiple-unit of control 
formulation were observed. Also, from Figure 36 A and B, it was observed that with 
increase in the amount of magnesium hydroxide in the extended release layer, amount of 
quinidine sulfate released at 2 hours in FaSSGF and at additional 22 hours in FaSSIF 
were decreased compared to control formulations.
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Due to the presence of magnesium hydroxide in both the layers, reduction in drug 
release was observed. This was attributed to increase in both microenvironmental pH and 
bulk media pH which leads to reduction in solubility of quinidine sulfate. The values of 
microenvironmental pH were 7.9, 8.4, and 9.3 for formulations Q25, Q50, and Q75, 
respectively, in both FaSSGF and FaSSIF (Table 16). Also, the bulk media pH with 3-
unit bilayer ADERT were 8.7, 8.9, and 9.1, respectively, from formulations Q25, Q50, 
and Q75 in FaSSGF at 2 hours and 7.8, 8.2, and 8.6 in FaSSIF at additional 22 hours 
(Figure 37). Bulk media pH with 5-unit bilayer ADERT were 9.3, 9.35, and 9.4, 
respectively, from formulations Q25, Q50, and Q75 in FaSSGF at 2 hours and 8.6, 8.8, 
and 9.2 in FaSSIF at additional 22 hours (Figure 37).  
 
The change in both bulk media and microenvironmental pH values led to 
reduction in solubility of drug (Figure 31) which leads to reduction in diffusion of the 
drug from various ADERT formulations. Accordingly, consuming multiple-unit ADERT 
of formulations Q25, Q50, and Q75 formulated with an opioid drug with pKa of 8.5 (like 
quinidine sulfate) might lead to a reduction in euphoric effect of opioids.  
 
5.2.5 Effect of alkalizing agent as a chemical barrier on dipyridamole-loaded 
bilayer ADERT 
5.2.5.1. Abuse deterrent potential of dipyridamole-loaded bilayer ADERT 
Abuse deterrent potential of dipyridamole-loaded bilayer ADERT was 
characterized using hardness testing as a physical barrier and drug extraction study as a 
chemical barrier study. Hardness of the formulations D1 was found to be 45.90  0.70 kg. 
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Drug extraction of formulation D1 is presented in Figure 42. Based on Figure 42 
A, it was observed drug extraction was reduced in all the solvents used as compared to 
the control formulation. It was reduced due to increased pH of the extraction media 
(Figure 42 B) due to presence of magnesium hydroxide. This increased pH (>10.3) leads 
to reduced solubility of dipyridamole (Figure 43) and thereby resulting in reduced drug 
diffusion from the polymeric matrix.  
 
5.2.5.2. Effect of magnesium hydroxide on in-vitro drug release from oral 
multiple-unit abuse of dipyridamole-loaded bilayer ADERT 
Drug release profiles for single and multiple unit ADERT from control and D1 
formulations are presented in Figure 38. Based on Figure 38, drug release profile for 
single unit control formulation was incomplete and 15.5±0.9 mg of drug released at the 
end of 24 hours of study. This incomplete drug release was observed due to shift in pH by 
use of FaSSGF for 2 hours followed by FaSSIF for additional 22 hours and thereby 
solubility of dipyridamole changed with change in media. From Figure 40, it was 
observed that after addition of FaSSIF, the pH of the media shifted to 6.5. Due to limited 
solubility of dipyridamole in the FaSSIF at pH 6.5 [solubility of 0.051±0.011 mg/mL at 
pH 6.5 (Figure 43)] which leads to incomplete release of dipyridamole (due to saturation 
of the drug in the dissolution vessel) from the single unit control and D1 formulations.  
 
Also, drug release from 3-and 5-unit control formation showed higher drug 
release in the FaSSGF and the drug release reduced in the FaSSIF. This type of drug 
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release was observed due to higher solubility of dipyridamole in FaSSGF (27.0±0.9 
mg/mL in FaSSGF pH 1.6) and reduced solubility in FaSSIF (0.051±0.011 mg/mL in in 
FaSSGF pH 6.5). Thereby, based on Equation 2, reduced solubility of the drug in FaSSIF 
resulted in reduced drug release in FaSSIF. On the other hand, drug release from 3-and 5-
unit D1 formation showed minimal drug release in both the medias. This minimal drug 
release was due to release of higher amount of magnesium hydroxide leading to increased 
pH of the media, thereby reduced solubility of dipyridamole. 
 
Figure 33 reflects effect of alkalizing agents on in-vitro drug release profiles from 
oral multiple-unit of dipyridamole-loaded bilayer ADERT of formulation D1 in FaSSGF 
for 2 hours and their comparison with control formulation. Drug release was found to be 
similar for single unit control and D1 formulations in FaSSGF. Limited amount of 
magnesium hydroxide released and pH of the media (Figure 41) was found to be similar 
for both the formulations. However, with multiple unit (3-and 5-unit) drug release study 
in FaSSGF significant reduction in drug release was observed (Figure 40). This was 
attributed to increase in the pH of bulk medium at 5.12 ±0.12 and 9.24±0.10 for 3-and 5-
unit of D1 formulation, respectively. Drug solubility at pH 5.1 was found to be 0.23±0.03 
mg/mL and at pH 9.2  to be 0.015±0.001 mg/mL. Based on Equation 3, these reduced 
solubilities at various pH leads to precipitation of the drug and thereby reduction in drug 
release was observed.  
 
The change in bulk media pH in FaSSGF led to reduction in solubility, and lower 
solubility of drug in the FaSSIF leads to reduction in diffusion of the drug from the D1 
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formulation with multiple unit release study. Accordingly, administering multiple-unit 
ADERT of formulations D1 formulated with an opioid drug with pKa of 6.5 (like 
dipyridamole) might lead to a reduction in euphoric effect of the opioid.
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6. CONCLUSION 
In this investigation, bilayer ADERTs of opioids could be successfully developed 
from an HPMC K100M matrix and novel MCC KG-1000 formulated in extended release 
layer coupled with an alkalizing agent in pH modifying layer using various model drugs. 
HPMC K100M and MCC KG-1000 were selected based on preliminary studies i.e., 
hardness, syringe-ability, and drug extraction. Bilayer ADERTs were developed and 
based on multiple-unit in-vitro drug release studies, magnesium hydroxide was selected 
as an alkalizing agent that was incorporated not only in pH modifying layer, but also in 
extended-release layers of bilayer ADERTs. The singe-unit drug release for the bilayer 
ADERTs was found to be similar to that of control formulation. whereas the multiple-unit 
drug release revealed that the drug release was reduced significantly compared to control 
formulation for all the model drugs. This indicates that the bilayer ADERTs approach 
could minimize oral multiple-unit abuse by modifying both micro-environmental and 
bulk media pH resulted in low solubility of drug suggesting their potential to minimize 
drug abuse.
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SUGGESTIONS FROM COMMITTEE MEMBERS 
1. Perform drug release study for Formulations F6 and F12 
Drug release study for formulations F6 and F12 was performed as per similar 
method as described in section 4.4.1.2.1 and the result of drug release study shown in 
Figure 44. Based on the drug release study, it was observed that both the formulations 
show similar drug release profile. This could be attributed due to high molecular weight 
of both PEO 7M (present in formulation F6) and HPMC K100M (present in formulation 
F12) and it leads to swelling of polymers in the aqueous environment. The drug release 
slowly from high swellable polymeric matrix and releases drug up to 24 hours. Also, 
similar drug release study supports the drug extraction study where both formulations 
shown similar drug extraction in all the solvent used. Hence, HPMC K100M can be a 
better alternative compared to PEO based on better abuse deterrent potential and similar 
drug release behavior.  
 
2. Perform inject-ability study for formulations F6 and F12 
Powder sample (of prepared ADERT) of 500 mg (i.e., one tablet) from F6 and 
F12 formulations was weighed accurately and transferred into separate 20 ml scintillation 
vials, each containing 10 ml of commonly injectable solvents that are distilled water, 
10%, and 40% ethanol, respectively, at room temperature. The scintillation vials were 
vortexed for 30 seconds and left for hydration for 30 min before the tests. The prepared 
solution was manually inserted into the syringe and needle was attached to the syringe.  
Inject-ability study of ADERT powder blend was performed by TA.XTPlus Texture 
Analyzer (Texture Technologies Corp., Hamilton, MA) equipped with a syringe assembly 
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set. A 5 ml syringe fitted with a 21-gauge needle was used for each test. Tension mode 
was set for 1 mm/s test speed and 0.05 N trigger force. The syringe plunger was set to 
move a distance of 40 mm in plunging direction. The target mode was set to record force 
that the sample plunger experience while pushing the solutions.  
The results of inject-ability study are shown in Figure 45 and force required to 
push the syringe is displayed in Table 17. Based on the results it was observed that 
formulation F12 shows higher force in all the solvents used compared to that of 
formulation F6. This was observed due to presence of HPMC K100M in formulation 
F12, which has higher swelling capacity compared to PEO 7M (present in formulation 
F6). Apart from that, the Also, the force was increased in hydroalcoholic solvents 
compared to water. This supports the viscosity study in hydroalcoholic solvents, since the 
viscosity of both polymers increases in hydroalcoholic solvents that leads to increased 
force for inject-ability.  
 
3. Limitation of the research  
The objective of the research is to minimize opioid overdose crisis. The studies 
conducted were aimed to minimize abuse potential for multiple-unit oral ingestion and 
reduce intravenous injection abuse.  
Based on the outcome of the studies, when multiple-unit intact bilayer ADERTs 
taken, the drug release will be reduced based on reduced solubility of the drug at higher 
pH environment. However, when crushed ADERTs taken orally, it will reduce drug 
release up to 2 hours, and thereafter the higher amount of drug will be available for the 
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absorption. Hence, the concept of bilayer ADERT with alkalizing agent is effective to 
reduce multiple-unit drug release only when intact bilayer tablets taken.  
Also, even the hardness of the tablets was found to be around 50 kg, they can still 
be reduced in smaller particles by using coffee grinder and can be abused by nasal 
insufflation. Particle size distribution of formulation F12 was carried out by performing 
physical manipulation. A coffee grinder (Brew berry, Bangkok) was used for physical 
manipulation of the ADERT. The ADERT (10-units) were subjected to high shear 
grinding for 2 min using a coffee grinder and the resultant material was subjected to 
particle size distribution by sieve analysis. The crushed material was applied to sieve 
stack which included U.S. Standard sieves no. 35 (500 µm), no. 40 (425 µm), no. 50 (300 
µm), no. 80 (180 µm), no. 120 (125 µm), and no. 170 (90 µm). The sieves were set on an 
electric sieve shaker for 5 minutes that operates in both vertical and horizontal tapping. 
After that, the materials were collected from each sieve and the percentage weight of 
powder collected on each sieve was determined. The percent of particles with size less 
than 500mm was also recorded. Similar study was performed on cured ADERT where, 
ADERTs subjected for 130 ºC for 30 minutes in hot air oven to increase physical strength 
in terms of hardness and cool down for 30 minutes and subjected to particle size 
distribution study.  
The results of particle size distribution study are displayed in Table 18. Based on 
the outcomes it was observed that more than 40% of the crushed particles found to be less 
than 500 micron for both before and after curing at higher temperature. There was no 
significant difference observed after curing ADERTs at higher temperature. It was 
observed due to high glass transition temperature of the polymer HPMC K100M and that 
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leads to minimum impact on the hardness. Hence, the selected formulation F12 can be 
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Table 2: Classification of polymers used for extended release characteristics 
Sr. 
No. 
Class of material Example References 
1 Hydrophilic polymers   
 1.1 Natural gums 
Guar gum, locust bean gum, tragacanth, 





Methyl cellulose, hydroxy propyl cellulose 
(HPC), hydroxy propyl methyl cellulose 
(HPMC) K4M, K15M, K100M, sodium 













Polyethylene oxide (PEO)-100000, PEO-
300000, PEO-1M, PEO-3M, PEO-7M 
homopolymers and copolymers of acrylic 






Carbopol-934, carbopol-907, carbopol-940 (64–69) 
2 Lipids 
Carnauba wax in combination with stearyl 
alcohol, beeswax, Compritol, Gelucire 
43/01, 39/01, 33/01, 50/02, and 54/02 
(65,69,73,7
4) 
3 Hydrophobic polymers 
Ethylcellulose, hypromellose acetate 
succinate, cellulose acetate, cellulose 
acetate propionate, methacrylic copolymers, 
polyvinyl acetate, polyethylene 
(65–67,69) 
4 Biodegradable polymers 
Poly lactic acid (PLA), poly glycolic acid 
(PGA), poly (lactide-co-glycolide) (PLGA), 
polyhydroxybutyrate (PHB), poly (e-
caprolactone) (PCL), polyamide, 














































































































Table 4: List of common aversion agents used in abuse deterrent formulations (24) 






eucalyptus oil, menthol, sucrose 
octa-acetate and other sucrose 
derivatives 
Causes a bitter taste to reduce 
abuse by oral or inhalation 
Emetic agent Cephaeline, ipecac, zinc sulfate 
Causes vomiting if greater 
than prescribed amount is 
ingested 
Gelling agent 
Carbomer, HPMC, poly(vinyl 
alcohol), PEO 
Produce nasal discomfort 
upon gelling in contact with 
mucous membrane 
Irritant agent 
Capsaicin and other 
capsaicinoids, citric acid and 
other acids, surfactants (e.g. 
sodium lauryl sulfate, 
poloxamer, sorbitan monoesters, 
glyceryl mono-oleates) 
Induces pain and irritation of 
abuser's mucous membrane 




Aloin, bisacodyl, casanthranol, 
castor oil, senna, sodium dioctyl 
sulfosuccinate 
Causes stools to loosen and/or 
increase bowel movements if 
greater than prescribed 
amount is ingested 
Staining agent 
Beta-Carotene, food, drug and 
cosmetic color (e.g., indigo 
carmine) and other dyes and 
lakes 
Stain tissues in contact with 




Causes warm flushing 
syndrome, itching and 
sweating effects 
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Table 5: Effect of polymeric solutions (2% w/v) as a physical barrier: Swelling behavior 
of polymers (data are presented as mean  standard deviation, n = 3) 
Polymer type 
Swelling behavior 
Water 10% Ethanol 40% Ethanol 70% IPA 0.1N HCl 
Xanthan gum     X 
Corn Starch     X 
Gelrite gum     X 
Chitosan X X X X  
Locust bean 
gum 
    X 
Na CMC     X 
Methyl 
cellulose 
     
Carbopol 907      
Carbopol 940      
PEO 5M      
PEO 7M      
HPMC K15M      
HPMC K100M      
Note:  represents swelling in given solvent, and X represents did not swell in 
given solvent 
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357.93 9.52 4.06 4.19 (76) 
Codeine phosphate 397.40 9.19 1.40 100000 (77) 
Methadone 309.44 9.12 4.14 5.90 (78) 
Morphine sulfate 668.80 9.12 0.89 10200 (79) 
Fentanyl 336.47 8.77 4.05 24 (80) 
Hydrocodone 
bitartrate 
449.46 8.61 2.13 62000 (81) 
Hydromorphone 
HCl 
321.80 8.59 0.11 4390 (82) 
Oxycodone HCl 351.80 8.53 1.04 100000 (83) 
Oxymorphone 301.33 8.21 0.83 25600 (84) 
Meperidine HCl 283.79 8.16 2.90 62000 (85) 
Remifentanil 376.40 7.10 1.75 591 (85) 
Alfentanil HCl 471.00 6.50 2.20 252 (85) 
Model drugs 
Propranolol HCl 295.80 9.45 2.58 50000 (86) 
Quinidine sulfate 746.90 8.50 2.82 11000 (87) 
Dipyridamole 504.60 6.40 1.52 922  
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Table 7: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in various solvents at 100 rpm 
Polymer 






0.1 N HCl 70 % IPA 
PEO 7M 286  11 306  32 423  29 200  3 330  4 
Carbopol 940 287  52 330  7 485  25 NA 377  10 
Carbopol 71G 117  8 145  12 262  15 NA 217  25 
HPMC K15M 288  25 317  4 415  15 199  3 200  9 
Methyl 
cellulose 
73  2 128  7 229  11 81  5 121  5 
PEO 5M 202  6 208  8 302  6 108  10 217  25 
HPMC K100 
M* 
737  22 820  16 952  13 609  49 502 28 
*Represents significantly different from other polymers p<0.05; data are presented as 
mean  standard deviation, n = 3 
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Table 8: Effect of polymeric solutions (2% w/v) as a physical barrier: Syringe-ability 























PEO 7M 13.5  2.0 3.1  0.6 13.3  0.9 2.9  0.9 
14.7  
1.2 
1.0  0.2 
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Table 9: Comparison of hardness of tablet formulations, formulated with screened 
polymers containing 40 mg metformin HCl in each tablet (data represent mean ± standard 
deviation, n = 3). 
Formulation 
code 
Type of polymer Type of diluent Hardness (kg) 
F1 PEO 7M MCC PH-101 33.3  1.1 
F2 PEO 7M MCC PH-102 33.1  0.2 
F3 PEO 7M MCC UF-702 35.6  0.5 
F4 PEO 7M MCC UF-711 37.0  1.0 
F5 PEO 7M MCC KG-802 41.6  1.8 
F6 PEO 7M MCC KG-1000 41.1  0.8 
F7 HPMC K100 M MCC PH-101 29.6  1.2 
F8 HPMC K100 M MCC PH-102 28.6  0.6 
F9 HPMC K100 M MCC UF-702 31.9  1.6 
F10 HPMC K100 M MCC UF-711 35.2  1.3 
F11 HPMC K100 M MCC KG-802 40.2  0.7 
F12 HPMC K100 M MCC KG-1000 42.8  0.8 
Composition of tablets was drug, polymer, MCC, and magnesium stearate at 
ratio of 8:30:61.5:0.5. 
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Table 10: Syringe-ability parameters of metformin HCl-loaded ADERT in various 

















F1 14.1  0.8 3.5  0.2 13.8  2.1 3.0  0.4 15.8  0.8 1.7  0.1 
F2 14.4  0.8 2.6  0.5 14.88  1.0 2.3  0.4 15.1  1.0 1.7  0.5 
F3 14.2  2.0 3.0  0.4 14.7  1.6 2.2  0.1 14.3  2.0 1.8  0.2 
F4 12.8  2.4 2.8  0.2 14.1  2.0 2.8  0.1 13.7  1.8 0.9  0.4 
F5 13.5  1.3 2.2  0.2 15.3  1.4 2.1  0.4 14.6  4.0 2.2  0.1 
F6 14.8  1.2 1.6  0.5 14.4  2.6 2.5  0.3 14.7  0.6 2.2  0.3 
F7 16.3  1.6 0.9  0.1 17.3  1.0 0.7  0.1 18.7  3.0 0.3  0.2 
F8 16.6  1.1 0.6  0.1 18.1  1.3 0.5  0.1 18.5  2.3 0.3  0.1 
F9 16.5  0.6 0.7  0.3 17.7  0.3 0.4  0.1 19.3  1.4 0.3  0.2 
F10 17.9  3.2 0.5  0.3 18.6  0.5 0.5  0.0 20.2  5.1 0.2  0.0 
F11 16.0  0.5 0.8  0.2 16.3  0.6 0.4  0.2 18.3  0.7 0.4  0.1 
F12 17.0  0.4 0.6  0.2 17.4  0.1 0.4  0.0 19.8  2.0 0.2  0.0 
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Table 11: Effect of excipients as a chemical barrier: drug extraction study of metformin 




Water (%) 10% ethanol (%) 40% ethanol (%) 
5 min 30 min 5 min 30 min 5 min 30 min 
F1 2.9  0.1 6.0  0.5 2.3  0.1 5.1  0.3 1.5  0.1 4.7  0.3 
F2 3.2  0.2 7.8  0.3 2.6  0.1 5.9  0.7 1.9  0.2 5.5  0.7 
F3 2.9  0.2 7.3  0.2 2.0  0.4 5.5  0.6 1.7  0.2 5.5  0.4 
F4 2.7  0.4 7.1  0.7 2.1  0.2 5.6  0.6 0.9  0.1 3.3  0.4 
F5 2.6  0.2 5.5  0.5 2.6  0.1 4.5  0.2 2.3  0.2 4.0  0.5 
F6 2.3  0.1 5.9  0.6 1.9  0.3 5.5  0.2 1.3  0.2 3.9  0.1 
F7 3.8  0.2 10.1  0.4 2.8  0.1 7.3  0.5 1.9  0.2 4.6  0.2 
F8 3.9  0.3 10.9  0.2 3.2  0.2 8.05  0.3 2.6  0.2 5.6  0.6 
F9 3.7  0.2 8.9  0.4 2.8  0.1 7.9  0.7 1.7  0.1 5.7  1.6 
F10 3.2  0.3 8.8  0.4 2.7  0.3 8.0  0.5 2.0  0.3 5.8   0.3 
F11 3.1  0.4 8.3  0.3 2.8  0.1 7.0  0.3 2.0  0.1 5.0  0.2 
F12 2.3  0.2 6.5   0.1 1.8  0.1 5.7  0.2 1.7  0.1 3.8  0.2 
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Table 12: Screening of alkalizing agent to be incorporated in pH modifying layer of 
propranolol hydrochloride-loaded bilayer ADERT 
Composition 
pH modifying layer 
P1 (mg) P2 (mg) P3 (mg) P4 (mg) 
Kollidon CL-SF 10 10 10 10 
Magnesium stearate 1 1 1 1 
Magnesium hydroxide (MgOH2) 100 - - - 
Aluminum hydroxide [Al(OH)3] - 100 - - 
Calcium carbonate (CaCO3) - - 100  
Calcium hydroxide [Ca(OH)2] - - - 100 
MCC KG-1000 q.s. to 200 q.s. to 200 q.s. to 200 q.s. to 200 
Note: All formulations contain similar extended release layer (total amount: 500 mg) 
composed of propranolol hydrochloride (40 mg), HPMC K100M (150 mg), 
magnesium stearate (2.5 mg), and MCC KG-1000 (307.5 mg). Control formulation 
contains similar composition as of an extended release layer 
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Table 13: Formulation compositions of propranolol hydrochloride-loaded bilayer 
ADERT formulated with various amount of magnesium hydroxide in extended release 
layer 
Composition 
Extended release layer 
P25 (mg) P50 (mg) P75 (mg) 
Propranolol HCl 40 40 4 
HPMC K 100M 150 150 150 
Magnesium stearate 2.5 2.5 2.5 
Magnesium hydroxide 25 50 75 
MCC KG-1000 q.s. to 500 q.s. to 500 q.s. to 500 
All formulations contain similar pH modifying layer (total amount: 200 mg) 
composed of Kollidon CL-SF (10 mg), magnesium hydroxide (100 mg), 
magnesium stearate (1 mg), and MCC KG-1000 (89 mg). Control formulation 
contains similar composition as of an extended release layer 
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Table 14: Formulation compositions of quinidine sulfate and dipyridamole-loaded bilayer 
ADERT 
Composition 
Extended release layer 
Q1 (mg) D1 (mg) 
Quinidine sulfate 40 - 
Dipyridamole - 40 
HPMC K 100M 150 150 
Magnesium stearate 2.5 2.5 
MCC KG-1000 q.s. to 500 q.s. to 500 
All formulations contain similar pH modifying layer (total amount: 200 mg) 
composed of Kollidon CL-SF (10 mg), magnesium hydroxide (100 mg), 
magnesium stearate (1 mg), and MCC KG-1000 (89 mg). Control formulation 
contains similar composition as of an extended release layer 
 
Table 15: Formulation compositions of quinidine sulfate-loaded bilayer ADERT 
formulated with various amount of magnesium hydroxide in extended release layer 
Composition 
Extended release layer 
Q25 (mg) Q50 (mg) Q75 (mg) 
Quinidine sulfate 40 40 40 
HPMC K 100M 150 150 150 
Magnesium stearate 2.5 2.5 2.5 
Magnesium hydroxide 25 50 75 
MCC KG-1000 q.s. to 500 q.s. to 500 q.s. to 500 
All formulations contain similar pH modifying layer (total amount: 200 mg) 
composed of Kollidon CL-SF (10 mg), magnesium hydroxide (100 mg), 
magnesium stearate (1 mg), and MCC KG-1000 (89 mg). Control formulation 
contains similar composition as of an extended release layer 
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Table 16: Microenvironmental pH for various formulations (data represent mean ± 
standard deviation, n = 3) 
Drug Solvent 
Formulation code 
Control P25 P50 P75 
Propranolol 
HCl 
Water 5.56  0.05 7.93  0.14 8.56  0.11 8.88  0.15 
FaSSGF 2.85  0.14 7.95  0.13 8.39  0.10 8.95  0.14 
FaSSIF 6.57  0.04 7.89  0.16 8.30  0.15 8.84  0.16 
Quinidine 
sulfate 
Water 6.00  0.20 7.85  0.10 8.21  0.10 9.32  0.20 
FaSSGF 3.90  0.03 7.90  0.12 8.40  0.24 9.19  0.16 
FaSSIF 6.56  0.06 7.98  0.08 8.38  0.24 9.25  0.12 
 
Table 17: Effect of polymeric solutions (2% w/v) as a physical barrier: Inject-ability 
force of polymeric solutions (data represent mean ± standard deviation, n = 3) 
Formulation code Solvent Force (N) 
F6 
Water 4.73  1.58 
10% ethanol 7.40  0.67 
40% ethanol 9.05  1.91 
F12 
Water 13.23  2.53 
10% ethanol 19.81  2.16 





Table 18: Particle size-distribution of crushed tablets (data represent mean ± standard 










35 500 39.01  2.52 44.11  5.64 
40 425 7.77  1.46 6.18  0.94 
50 300 11.66  0.75 10.12  2.00 
80 180 11.39  0.46 9.10  1.65 
120 125 6.16  0.70 4.78  1.22 
170 90 5.90  0.35 5.76  0.39 






Figure 1. Calibration curve of metformin HCl assayed by UV-spectroscopy 
 
 
Figure 2. Calibration curve of propranolol HCl assayed by HPLC method 
















y = 0.0779x - 0.0033
R² = 0.9999





















Figure 3. Calibration curve of quinidine sulfate assayed by HPLC method 
 
 
Figure 4. Calibration curve of dipyridamole assayed by HPLC method 
















y = 5.0694x - 1.2747
R² = 0.9998



















Figure 5. Illustration of the process for making bilayer ADERT. (a) Compression of first 
layer; (b) addition and compression of second layer; (c) Ejection of bilayer tablet from 
die. P1: compression pressure 1 (200 lbs); P2: compression pressure 2 (2500 lbs) [Figure 
adapted from reference: (88)] 
 88 
 
Figure 6: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in water (data represent mean  standard deviation, n = 3)


































Figure 7: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in 10% ethanol(data represent mean  standard deviation, n = 3) 




































Figure 8: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in 40% ethanol (data represent mean  standard deviation, n = 3) 



































Figure 9: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in 0.1N HCl (data represent mean  standard deviation, n = 3) 































Figure 10: Effect of polymeric solutions (2% w/v) as a physical barrier: Viscosity of 
polymers in 70% isopropanol (data represent mean  standard deviation, n = 3) 

































Figure 11: Effect of polymeric solutions (2% w/v) as a physical barrier: Heat induced 
viscosity at 100 rpm (data represent mean  standard deviation, n = 3)

























Figure 12: Effect of polymeric solutions (2% w/v) as a physical barrier: Syringe-ability 
profiles in various solvents. (data represent mean, n = 3-5)
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Figure 13: Effect of excipients as a physical barrier: Syringe-ability profile of 
formulations F1-F12, A: water (F1-F6), B: 10% ethanol (F1-F6), C: 40% ethanol (F1-
F6), D: water (F7-F12), E: 10% ethanol (F7-F12), and F: 40% ethanol (F7-F12). Data 







































Figure 14: Effect of excipients as a chemical barrier: drug extraction study in various 
solvents, A) formulation F1-F6, B) formulation F7-F12 (data represent mean ± standard 
deviation, n = 3)  




























































10% Ethanol (5 minutes)
10% Ethanol (30 minutes)
40% Ethanol (5 minutes)








Figure 15: Effect of excipients as a chemical barrier: drug extraction study from 
formulations P, Q, and D in various solvents (data represent mean ± standard deviation, n 
= 3) 
 






























10% Ethanol (5 minutes)
10% Ethanol (30 minutes)
40% Ethanol (5 minutes)






Figure 16: In-vitro drug release profile of propranolol HCl-loaded bilayer ADERT of 
formulation P1, P2, P3, and P4 from A) 1-unit, B) 3-unit, and C) 5-unit in FaSSGF for 2 
hours followed by FaSSIF for additional 22 hours and their comparison with control 
formulation. (data represent mean  standard deviation, n = 3; control formulation 
represents formulation P) 
 












































Figure 17: Cumulative % In-vitro drug release profile of propranolol HCl-loaded bilayer 
ADERT of formulation P1, P2, P3, and P4 from A) 1-unit, B) 3-unit, and C) 5-unit in 
FaSSGF for 2 hours followed by FaSSIF for additional 22 hours and their comparison 
with control formulation. (data represent mean  standard deviation, n = 3; control 
formulation represents formulation P) 












































Figure 18: Effect of alkalizing agents on in-vitro drug release profiles from oral multiple-
unit of propranolol HCl-loaded ADERT of formulation P1, P2, P3, and P4 in FaSSGF for 
2 hours and their comparison with control formulation to minimize the potential abuse. 
(** represents significantly different from other formulations p<0.005; data are presented 
as mean  standard deviation, n = 3; control formulation represents formulation P) 





























Figure 19: Effect of alkalizing agents on pH of in-vitro drug release media from oral 
multiple-unit of propranolol HCl-loaded bilayer ADERT of A) formulation P1, B) 
formulation P2, C) formulation P3, and D) formulation P4, in FaSSGF for 2 hours 
followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3; control formulation represents formulation P)

























































Figure 20: Effect of excipients as a chemical barrier: A) drug extraction study from 
formulations P1, P2, P3, and P4 in various solvents B) effect of alkalizing agents on pH 
of drug extraction media at 30 minutes and their comparison with control formulation to 
minimize the potential abuse (data represent mean ± standard deviation, n = 3; control 
formulation represents formulation P)





























10% Ethanol (5 minutes)
10% Ethanol (30 minutes)
40% Ethanol (5 minutes)































Figure 21: pH-dependent solubility profile of propranolol HCl (data represent mean  
standard deviation, n = 3) 
 
 
Figure 22: Effect of amount of magnesium hydroxide on in-vitro drug release profiles 
from oral single-unit of propranolol HCl-loaded bilayer ADERT of formulation P25, P50, 
and P75 in FaSSGF for 2 hours followed by FaSSIF for additional 22 hours and their 
comparison with control formulation. (data represent mean  standard deviation, n = 3; 
control formulation represents formulation P) 
 



















































Figure 23: Effect of amount of magnesium hydroxide on cumulative % in-vitro drug 
release profiles from oral single-unit of propranolol HCl-loaded bilayer ADERT of 
formulation P25, P50, and P75 in FaSSGF for 2 hours followed by FaSSIF for additional 
22 hours and their comparison with control formulation. (data represent mean  standard 
deviation, n = 3; control formulation represents formulation P) 






























Figure 24: Effect of amount of magnesium hydroxide on in-vitro drug release profiles 
from oral multiple-unit of propranolol HCl-loaded bilayer ADERT of A) formulation 
P25, B) formulation P50 and C) formulation P75 in FaSSGF for 2 hours followed by 
FaSSIF for additional 22 hours and their comparison with control formulation to 
minimize the potential abuse. (data represent mean  standard deviation, n = 3, control 
formulation represents formulation P) 




























































Figure 25: Effect of amount of magnesium hydroxide on cumulative % in-vitro drug 
release profiles from oral multiple-unit of propranolol HCl-loaded bilayer ADERT of A) 
formulation P25, B) formulation P50 and C) formulation P75 in FaSSGF for 2 hours 
followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3, control formulation represents formulation P) 



























































Figure 26: Effect of amount of magnesium hydroxide on amount of drug release A) at 2 
hours in fasted state simulated gastric fluid (FaSSGF) and B) at additional 22 hours in 
fasted state simulated intestinal fluid (FaSSIF) from oral multiple-unit of propranolol 
HCl-loaded bilayer ADERT of formulations P25, P50 and P75 and their comparison with 
the control formulation. (**, ***, and **** represents significantly different from other 
formulations p<0.005, 0.005, and 0.0005, respectively; data are presented as mean  
standard deviation, n = 3; control formulation represents formulation P) 



































































Figure 27: Effect of alkalizing agents on pH of in-vitro drug release media from 
propranolol HCl-loaded bilayer ADERT of A) 1-unit, B) 3-unit, and C) 5-unit in FaSSGF 
for 2 hours followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3; control formulation represents formulation P)








































Figure 28: In-vitro drug release profile of quinidine sulfate-loaded bilayer ADERT of 
formulation Q1 from 1, 3, and 5-unit in FaSSGF for 2 hours followed by FaSSIF for 
additional 22 hours and their comparison with control formulation. (data represent mean 
 standard deviation, n = 3; control formulation represents formulation Q)


































Figure 29: Cumulative % in-vitro drug release profile of quinidine sulfate-loaded bilayer 
ADERT of formulation Q1 from 1, 3, and 5-unit in FaSSGF for 2 hours followed by 
FaSSIF for additional 22 hours and their comparison with control formulation. (data 
represent mean  standard deviation, n = 3; control formulation represents formulation Q)
































Figure 30: Effect of excipients as a chemical barrier: A) drug extraction study from 
formulation Q1 in various solvents B) effect of alkalizing agents on pH of drug extraction 
media at 30 minutes and their comparison with control formulation to minimize the 
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Figure 31: pH-dependent solubility profile of quinidine sulfate (data represent mean  
standard deviation, n = 3) 
 
 
Figure 32: Effect of amount of magnesium hydroxide on in-vitro drug release profiles 
from oral single-unit of quinidine sulfate-loaded bilayer ADERT of formulation Q25, 
Q50, and Q75 in FaSSGF for 2 hours followed by FaSSIF for additional 22 hours and 
their comparison with control formulation. (data represent mean  standard deviation, n = 
3; control formulation represents formulation Q) 















































Figure 33: Effect of amount of magnesium hydroxide on cumulative % in-vitro drug 
release profiles from oral single-unit of quinidine sulfate-loaded bilayer ADERT of 
formulation Q25, Q50, and Q75 in FaSSGF for 2 hours followed by FaSSIF for 
additional 22 hours and their comparison with control formulation. (data represent mean 
 standard deviation, n = 3; control formulation represents formulation Q) 
 






























Figure 34: Effect of amount of magnesium hydroxide on in-vitro drug release profiles 
from oral multiple-unit of quinidine sulfate-loaded bilayer ADERT of A) formulation 
Q25, B) formulation Q50 and C) formulation Q75 in FaSSGF for 2 hours followed by 
FaSSIF for additional 22 hours and their comparison with control formulation to 
minimize the potential abuse. (data represent mean  standard deviation, n = 3; control 
formulation represents formulation Q) 
 



























































Figure 35: Effect of amount of magnesium hydroxide on cumulative % in-vitro drug 
release profiles from oral multiple-unit of quinidine sulfate-loaded bilayer ADERT of A) 
formulation Q25, B) formulation Q50 and C) formulation Q75 in FaSSGF for 2 hours 
followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3; control formulation represents formulation Q) 
 




























































Figure 36: Effect of amount of magnesium hydroxide on amount of drug release A) at 2 
hours in fasted state simulated gastric fluid (FaSSGF) and B) at additional 22 hours in 
fasted state simulated intestinal fluid (FaSSIF) from oral multiple-unit of quinidine 
sulfate-loaded bilayer ADERT of formulations Q25, Q50 and Q75 and their comparison 
with the control formulation. (*, **, ***, and **** represents significantly different from 
other formulations p<0.05, 0.005, 0.005, and 0.0005, respectively; data are presented as 
mean  standard deviation, n = 3; control formulation represents formulation Q) 
 


































































Figure 37: Effect of alkalizing agents on pH of in-vitro drug release media from 
propranolol HCl-loaded bilayer ADERT of A) 1-unit, B) 3-unit, and C) 5-unit in FaSSGF 
for 2 hours followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3; control formulation represents formulation Q) 
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Figure 38: In-vitro drug release profile of dipyridamole-loaded bilayer ADERT of 
formulation D1 from 1, 3, and 5-unit in FaSSGF for 2 hours followed by FaSSIF for 
additional 22 hours and their comparison with control formulation. (data represent mean 
 standard deviation, n = 3; control formulation represents formulation D) 
 































Figure 39: Cumulative % in-vitro drug release profile of dipyridamole-loaded bilayer 
ADERT of formulation D1 from 1, 3, and 5-unit in FaSSGF for 2 hours followed by 
FaSSIF for additional 22 hours and their comparison with control formulation. (data 
represent mean  standard deviation, n = 3; control formulation represents formulation D) 






























Figure 40: Effect of alkalizing agents on in-vitro drug release profiles from oral multiple-
unit of dipyridamole-loaded ADERT of formulation D1 in FaSSGF for 2 hours and their 
comparison with control formulation to minimize the potential abuse. (**** represents 
significantly different from other formulations p< 0.0005; data are presented as mean  
standard deviation, n = 3; control formulation represents formulation Q)



























Figure 41: Effect of alkalizing agents on pH of in-vitro drug release media from oral 
multiple-unit of dipyridamole-loaded bilayer ADERT of formulation D1 in FaSSGF for 2 
hours followed by FaSSIF for additional 22 hours and their comparison with control 
formulation to minimize the potential abuse. (data represent mean  standard deviation, n 
= 3; control formulation represents formulation D)

















Figure 42: Effect of excipients as a chemical barrier: A) drug extraction study from 
formulation Q1 in various solvents B) effect of alkalizing agents on pH of drug extraction 
media at 30 minutes and their comparison with control formulation to minimize the 
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Figure 43: pH-dependent solubility profile of dipyridamole. (data represent mean  
standard deviation, n = 3)
























Figure 44: In-vitro drug release profiles from oral single-unit of metformin HCl-loaded 
ADERT of formulation F6 and F12 in FaSSGF for 2 hours followed by FaSSIF for 
additional 22 hours. (data represent mean  standard deviation, n = 3; control formulation 
represents formulation P) 
 



























Figure 45: Effect of polymeric solutions (2% w/v) as a physical barrier: Syringe-ability 
profiles in various solvents. (data represent mean, n = 3-5)
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